{"title_page": "Metformin", "text_new": "{{short description|Medication}}\n{{Good article}}\n{{Use dmy dates|date=February 2020}}\n{{Infobox drug\n| drug_name         = \n| INN               = \n| type              = <!-- empty -->\n| image = Metformin.svg\n| width = \n| alt               = \n| image2 = Metformin-from-xtal-3D-balls.png\n| width2 = \n| alt2              = \n| caption           = \n\n<!-- Clinical data -->\n| pronounce = {{IPAc-en|m|\u025b|t|\u02c8|f|\u0254\u02d0r|m|\u1d7b|n}}, {{respell|met|FOR|min}}\n| tradename = Fortamet, Glucophage, Glumetza, others\n| Drugs.com = {{drugs.com|monograph|metformin-hydrochloride}}\n| MedlinePlus = a696005\n| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->\n| licence_EU = Yes\n| DailyMedID = Metformin\n| licence_US = Metformin\n| pregnancy_AU = C\n| pregnancy_AU_comment = <ref name=\"Drugs.com pregnancy\">{{cite web | title=Metformin Use During Pregnancy | website=Drugs.com | date=10 September 2019 | url=https://www.drugs.com/pregnancy/metformin.html | access-date=4 February 2020}}</ref>\n| pregnancy_US = N\n| pregnancy_US_comment = <ref name=\"Drugs.com pregnancy\" />\n| pregnancy_category = \n| dependency_liability = \n| addiction_liability = \n| routes_of_administration = [[Oral administration|By mouth]]\n| class             = \n| ATCvet            = \n| ATC_prefix = A10\n| ATC_suffix = BA02\n| ATC_supplemental  = {{ATC|A10|BD23}} {{ATC|A10|BD02}} {{ATC|A10|BD18}} {{ATC|A10|BD11}} {{ATC|A10|BD25}} {{ATC|A10|BD22}} {{ATC|A10|BD14}} {{ATC|A10|BD16}} {{ATC|A10|BD17}} {{ATC|A10|BD05}} {{ATC|A10|BD15}} {{ATC|A10|BD07}} {{ATC|A10|BD10}} {{ATC|A10|BD13}} {{ATC|A10|BD20}} {{ATC|A10|BD08}} {{ATC|A10|BD03}} \n\n<!-- Legal status -->\n| legal_AU = S4\n| legal_AU_comment = \n| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->\n| legal_BR_comment = \n| legal_CA = Rx-only\n| legal_CA_comment = \n| legal_DE = <!-- Anlage I, II, III or Unscheduled-->\n| legal_DE_comment = \n| legal_NZ = <!-- Class A, B, C -->\n| legal_NZ_comment = \n| legal_UK = POM\n| legal_UK_comment = \n| legal_US = Rx-only\n| legal_US_comment = \n| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->\n| legal_UN_comment = \n| legal_status      = <!--For countries not listed above-->\n\n<!-- Pharmacokinetic data -->\n| bioavailability = 50\u201360%<ref name = D95>{{cite journal | vauthors = Dunn CJ, Peters DH | title = Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus | journal = Drugs | volume = 49 | issue = 5 | pages = 721\u201349 | date = May 1995 | pmid = 7601013 | doi = 10.2165/00003495-199549050-00007 }}</ref><ref name=D03>{{cite journal | vauthors = Hundal RS, Inzucchi SE | title = Metformin: new understandings, new uses | journal = Drugs | volume = 63 | issue = 18 | pages = 1879\u201394 | year = 2003 | pmid = 12930161 | doi = 10.2165/00003495-200363180-00001 }}</ref>\n| protein_bound = Minimal<ref name = D95 />\n| metabolism = Not by liver<ref name = D95 />\n| metabolites = \n| onset             = \n| elimination_half-life = 4\u20138.7 hours<ref name = D95 />\n| duration_of_action = \n| excretion = Urine (90%)<ref name = D95 />\n\n<!-- Identifiers -->\n| index_label = \n| index2_label = hydrochloride\n| CAS_number_Ref = {{cascite|correct}}\n| CAS_number = 657-24-9\n| CAS_number2_Ref = {{cascite|correct}}\n| CAS_number2 = 1115-70-4\n| PubChem = 4091\n| IUPHAR_ligand = 4779\n| DrugBank = DB00331\n| DrugBank_Ref      = \n| ChemSpiderID = 3949\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| UNII = 9100L32L2N\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII2 = 786Z46389E\n| UNII2_Ref = {{fdacite|correct|FDA}}\n| KEGG = D04966\n| KEGG_Ref = {{keggcite|correct|kegg}}\n| KEGG2 = C07151\n| KEGG2_Ref = {{keggcite|correct|kegg}}\n| ChEBI = 6801\n| ChEBI_Ref = {{ebicite|correct|EBI}}\n| ChEMBL = 1431\n| ChEMBL_Ref = {{ebicite|correct|EBI}}\n| NIAID_ChemDB      = \n| PDB_ligand        = \n| synonyms = ''N'',''N''-dimethylbiguanide<ref>{{cite journal | vauthors = Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, Conti F | title = Disposition of metformin (N,N-dimethylbiguanide) in man | journal = Clinical Pharmacology and Therapeutics | volume = 24 | issue = 6 | pages = 683\u201393 | date = December 1978 | pmid = 710026 | doi = 10.1002/cpt1978246683 }}</ref>\n\n<!-- Chemical and physical data -->\n| IUPAC_name = ''N'',''N''-Dimethylimidodicarbonimidic diamide\n| chemical_formula  = \n| C=4 | H=11 | N=5\n| molecular_weight = 129.164\n| SMILES = CN(C)C(=N)N=C(N)N\n| Jmol              = \n| StdInChI = 1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)\n| StdInChI_comment = \n| StdInChIKey = XZWYZXLIPXDOLR-UHFFFAOYSA-N\n| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}\n| density = 1.3\u00b10.1<ref name=\"chemsrc\">{{Cite web|url=https://www.chemsrc.com/en/cas/657-24-9_889579.html|title=metformin_msds}}</ref>\n| density_notes     = \n| melting_point = \n| melting_high      = \n| melting_notes     = \n| boiling_point = \n| boiling_notes     = \n| solubility = \n| sol_units         = \n| specific_rotation = \n}}\n\n<!-- Definition and medical uses -->\n'''Metformin''', marketed under the trade name '''Glucophage''' among others, is the [[first-line treatment|first-line]] medication for the treatment of [[diabetes mellitus type 2|type 2 diabetes]],<ref name=AHFS2016 /><ref name=Ann2016>{{cite journal | vauthors = Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S | title = Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis | journal = Annals of Internal Medicine | volume = 164 | issue = 11 | pages = 740\u201351 | date = June 2016 | pmid = 27088241 | doi = 10.7326/M15-2650 }}</ref> particularly in people who are [[overweight]].<ref>{{cite book |title=Clinical Obesity |date=2008 |publisher=John Wiley & Sons |location=Oxford |isbn=978-0-470-98708-7 |page=262 |edition=2nd |url=https://books.google.com/books?id=qGVnItPoPCYC&pg=PA262 |url-status=live |archive-url=https://web.archive.org/web/20170908185309/https://books.google.com/books?id=qGVnItPoPCYC&pg=PA262 |archive-date=2017-09-08}}</ref> It is also used in the treatment of [[polycystic ovary syndrome]].<ref name=AHFS2016 /> It is not associated with weight gain.<ref name=Pres2014>{{cite journal | vauthors =  | title = Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects | journal = Prescrire International | volume = 23 | issue = 154 | pages = 269\u201372 | date = November 2014 | pmid = 25954799 }}</ref> It is taken by mouth.<ref name=AHFS2016 />\n\n<!-- Side effects and mechanism -->\nMetformin is generally well tolerated.<ref>{{cite journal | vauthors = Triggle CR, Ding H | title = Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium | journal = Acta Physiologica | volume = 219 | issue = 1 | pages = 138\u2013151 | date = January 2017 | pmid = 26680745 | doi = 10.1111/apha.12644 }}</ref> Common side effects include [[diarrhea]], [[nausea]], and abdominal pain.<ref name=AHFS2016 /> It has a low risk of causing [[hypoglycemia|low blood sugar]].<ref name=AHFS2016 /> [[Lactic acidosis|High blood lactic acid level]] is a concern if the medication is prescribed inappropriately or in overly large doses.<ref name=\"pmid21617112\">{{cite journal | vauthors = Lipska KJ, Bailey CJ, Inzucchi SE | title = Use of metformin in the setting of mild-to-moderate renal insufficiency | journal = Diabetes Care | volume = 34 | issue = 6 | pages = 1431\u20137 | date = June 2011 | pmid = 21617112 | pmc = 3114336 | doi = 10.2337/dc10-2361 }}</ref> There is a risk of [[Lactic acidosis|High blood lactic acid level]], which can be life-threatening, in people with severe renal insufficiency who take metformin.<ref name=AHFS2016 /> While no clear harm comes from use during [[pregnancy]], [[insulin]] is generally preferred for [[gestational diabetes]].<ref name=AHFS2016 /><ref>{{cite journal | vauthors = Lautatzis ME, Goulis DG, Vrontakis M | title = Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review | journal = Metabolism | volume = 62 | issue = 11 | pages = 1522\u201334 | date = November 2013 | pmid = 23886298 | doi = 10.1016/j.metabol.2013.06.006 }}</ref> Metformin is a [[biguanide]] antihyperglycemic agent.<ref name=AHFS2016>{{cite web|title=Metformin Hydrochloride|url=https://www.drugs.com/monograph/metformin-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|access-date=2 January 2017|url-status=live|archive-url=https://web.archive.org/web/20161224162245/https://www.drugs.com/monograph/metformin-hydrochloride.html|archive-date=24 December 2016|df=}}</ref> It works by decreasing [[Gluconeogenesis|glucose production]] by the [[liver]] and increasing the insulin sensitivity of body tissues.<ref name=AHFS2016/>\n\n<!-- History, society, and culture -->\nMetformin was discovered in 1922.<ref name=Fis2010>{{cite book|last1=Fischer|first1=Janos|title=Analogue-based Drug Discovery II|date=2010|publisher=John Wiley & Sons|isbn=978-3-527-63212-1|pages=49|url=https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA49|url-status=live|archive-url=https://web.archive.org/web/20170908185310/https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA49|archive-date=2017-09-08|df=}}</ref> French physician Jean Sterne began study in humans in the 1950s.<ref name=Fis2010 /> It was introduced as a medication in France in 1957 and the United States in 1995.<ref name=AHFS2016 /><ref>{{cite book|last1=McKee|first1=Mitchell Bebel Stargrove, Jonathan Treasure, Dwight L.|title=Herb, nutrient, and drug interactions : clinical implications and therapeutic strategies|date=2008|publisher=Mosby/Elsevier|location=St. Louis, Mo.|isbn=978-0-323-02964-3|page=217|url=https://books.google.com/books?id=49kLK--eumEC&pg=PA217|url-status=live|archive-url=https://web.archive.org/web/20170908185309/https://books.google.com/books?id=49kLK--eumEC&pg=PA217|archive-date=2017-09-08|df=}}</ref> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]], the safest and most effective medicines needed in a [[health system]].<ref name=\"WHO21st\">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref> Metformin is the most widely used medication for diabetes taken by mouth.<ref name=Fis2010/> It is available as a [[generic medication]].<ref name=AHFS2016 /> The wholesale price in the [[developed world]] was between {{US$}}0.21 and $5.55 per month {{as of|2014|lc=yes}}.<ref>{{cite web|title=Metformin|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=508&searchYear=2014|access-date=11 January 2016|url-status=live|archive-url=https://web.archive.org/web/20170803055731/http://mshpriceguide.org/en/single-drug-information/?DMFId=508&searchYear=2014|archive-date=3 August 2017|df=}}</ref> In the United States, it costs {{US$|5}} to {{US$|25}} per month.<ref name=AHFS2016 /> In 2017, it was the fourth-most commonly prescribed medication in the United States, with more than 78 million prescriptions.<ref>{{cite web |title=The Top 300 of 2020 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=ClinCalc |accessdate=7 April 2020}}</ref><ref>{{cite web | title=Metformin Hydrochloride - Drug Usage Statistics | website=ClinCalc | date=23 December 2019 | url=https://clincalc.com/DrugStats/Drugs/MetforminHydrochloride | access-date=7 April 2020}}</ref>\n{{TOC limit}}\n\n== Medical uses ==\nMetformin is used to lower the blood sugar in those with [[type 2 diabetes]].<ref name=AHFS2016 />  It is also used as a second line agent for [[infertility]] in those with [[polycystic ovary syndrome]].<ref name=AHFS2016 /><ref name=Lord>{{cite journal | vauthors = Lord JM, Flight IH, Norman RJ | title = Metformin in polycystic ovary syndrome: systematic review and meta-analysis | journal = BMJ | volume = 327 | issue = 7421 | pages = 951\u20133 | date = October 2003 | pmid = 14576245 | pmc = 259161 | doi = 10.1136/bmj.327.7421.951 }}</ref>\n\n=== Type 2 diabetes ===\nThe [[American Diabetes Association]] and the [[American College of Physicians]] each recommend metformin as a first-line agent to treat type 2 diabetes.<ref name=\"comparative effectiveness\">{{cite journal | vauthors = Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S | title = Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations | journal = Annals of Internal Medicine | volume = 154 | issue = 9 | pages = 602\u201313 | date = May 2011 | pmid = 21403054 | pmc = 3733115 | doi = 10.7326/0003-4819-154-9-201105030-00336 }}</ref><ref name=\"Inzucchi SE, Bergenstal RM, Buse JB, et al. 1364\u201379\">{{cite journal | vauthors = Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR | title = Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | journal = Diabetes Care | volume = 35 | issue = 6 | pages = 1364\u201379 | date = June 2012 | pmid = 22517736 | pmc = 3357214 | doi = 10.2337/dc12-0413 }}</ref><ref name=ACP2012>{{cite journal | vauthors = Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P | title = Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians | journal = Annals of Internal Medicine | volume = 156 | issue = 3 | pages = 218\u201331 | date = February 2012 | pmid = 22312141 | doi = 10.7326/0003-4819-156-3-201202070-00011 | doi-access = free }}</ref> It is as effective as [[repaglinide]] and more effective than all other oral diabetes mellitus type 2 drugs.<ref>{{cite journal |vauthors=Jia Y, Lao Y, Zhu H, Li N, Leung SW |display-authors=3 |title=Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials |journal=Obes Rev |volume=20 |issue=1 |pages=1\u201312 |date=January 2019 |pmid=30230172 |doi=10.1111/obr.12753 |url=|doi-access=free }}</ref>\n\n==== Efficacy ====\nThe UK Prospective Diabetes Study, a large clinical trial performed in 1980\u201390s, provided evidence that metformin reduced the rate of adverse [[Circulatory system|cardiovascular]] outcomes in overweight patients with type 2 diabetes relative to other antihyperglycemic agents.<ref name = UKPDS>{{cite journal | vauthors =  | title = Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | journal = Lancet | volume = 352 | issue = 9131 | pages = 854\u201365 | date = September 1998 | pmid = 9742977 | doi = 10.1016/S0140-6736(98)07037-8 }}</ref>  However, accumulated evidence from other and more recent trials reduced confidence in the efficacy of metformin for cardiovascular disease prevention.<ref>{{cite journal | vauthors = Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL | title = Cardiovascular outcomes in trials of oral diabetes medications: a systematic review | journal = Archives of Internal Medicine | volume = 168 | issue = 19 | pages = 2070\u201380 | date = October 2008 | pmid = 18955635 | pmc = 2765722 | doi = 10.1001/archinte.168.19.2070 }}</ref><ref name=\"GroopBoussageon2012\">{{cite journal | vauthors = Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C | title = Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials | journal = PLOS Medicine | volume = 9 | issue = 4 | pages = e1001204 | year = 2012 | pmid = 22509138 | pmc = 3323508 | doi = 10.1371/journal.pmed.1001204 }}</ref> Outcomes are improved even in those with some degree of kidney disease, [[heart failure]], or [[chronic liver disease]].<ref>{{cite journal | vauthors = Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, Wang X, Tang S, Nagi A, Kosinski AS, Williams JW | title = Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review | journal = Annals of Internal Medicine | volume = 166 | issue = 3 | pages = 191\u2013200 | date = February 2017 | pmid = 28055049 | pmc = 5293600 | doi = 10.7326/M16-1901 }}</ref>\n\nTreatment guidelines for major professional associations including the [[European Association for the Study of Diabetes]], the European Society for Cardiology, and the [[American Diabetes Association]], now describe evidence for the cardiovascular benefits of metformin as equivocal.<ref name=\"Inzucchi SE, Bergenstal RM, Buse JB, et al. 1364\u201379\" /><ref>{{cite journal | vauthors = Ryd\u00e9n L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL | title = ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD\u2014summary | journal = Diabetes & Vascular Disease Research | volume = 11 | issue = 3 | pages = 133\u201373 | date = May 2014 | pmid = 24800783 | doi = 10.1177/1479164114525548 | doi-access = free }}</ref>\n\nIn 2017, the American College of Physicians's guidelines were updated to recognize metformin as the first-line treatment for type 2 diabetes. These guidelines supersede earlier reviews.  For example, a 2014 review found tentative evidence that people treated with [[sulfonylurea]]s had a higher risk of severe low blood sugar events (RR 5.64), though their risk of nonfatal cardiovascular events was lower than the risk of those treated with metformin (RR 0.67). Not enough data were available at that time to determine the relative risk of death or of death from heart disease.<ref>{{cite journal | vauthors = Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstr\u00f8m LH, Almdal T | title = Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis | journal = CMAJ Open | volume = 2 | issue = 3 | pages = E162\u201375 | date = July 2014 | pmid = 25295236 | pmc = 4185978 | doi = 10.9778/cmajo.20130073 }}</ref>\n\nMetformin has little or no effect on body weight in type 2 diabetes compared with [[placebo]],<ref name=\"Johansen1999\">{{cite journal|vauthors=Johansen K|title=Efficacy of metformin in the treatment of NIDDM. Meta-analysis|journal=Diabetes Care|volume=22|issue=1|date=January 1999|pages=33\u20137|issn=0149-5992|doi=10.2337/diacare.22.1.33|pmid=10333900}}</ref> in contrast to sulfonylureas which are associated with weight gain.<ref name=\"Johansen1999\" /> There is some evidence that metformin is associated with weight loss in obesity in the absence of diabetes.<ref name=\"Golay2007\">{{cite journal | vauthors = Golay A | title = Metformin and body weight | journal = International Journal of Obesity | volume = 32 | issue = 1 | pages = 61\u201372 | date = January 2008 | pmid = 17653063 | doi = 10.1038/sj.ijo.0803695 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Mead E, Atkinson G, Richter B, Metzendorf MI, Baur L, Finer N, Corpeleijn E, O'Malley C, Ells LJ | title = Drug interventions for the treatment of obesity in children and adolescents | journal = The Cochrane Database of Systematic Reviews | volume = 11 | pages = CD012436 | date = November 2016 | pmid = 27899001 | pmc = 6472619 | doi = 10.1002/14651858.CD012436 | hdl = 10149/620651 }}</ref> Metformin has a lower risk of [[hypoglycemia]] than the sulfonylureas,<ref name=\"Umesh\" /><ref name=\"Bolen\" /> although hypoglycemia has uncommonly occurred during intense exercise, calorie deficit, or when used with other agents to lower blood glucose.<ref name=\"isbn0071416137\">{{cite book | last1 = DiPiro | first1 = Joseph T. | last2 = Talbert | first2 = Robert L. | last3 = Yee | first3 = Gary C. | last4 = Matzke | first4 = Gary R. | last5 = Wells | first5 = Barbara G. | last6 = Posey | first6 = L. Michael | name-list-format = vanc |title=Pharmacotherapy: a pathophysiologic approach |publisher=McGraw-Hill |location=New York |year=2005 |isbn=978-0-07-141613-9 }}</ref><ref>[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18054 \"Glucophage package insert\"]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.</ref> Metformin modestly reduces [[low density lipoprotein|LDL]] and [[triglyceride]] levels.<ref name=\"Umesh\" /><ref name=\"Bolen\" />\n\n=== Polycystic ovarian syndrome ===\nIn those with [[polycystic ovarian syndrome]] (PCOS), tentative evidence shows that metformin use increases the rate of live births.<ref name=Mor2017>{{cite journal |vauthors=Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH |display-authors=3 |title=Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility |journal==Cochrane Database Syst Rev |date=November 2017 |volume=11 |pages=CD003053 |doi=10.1002/14651858.CD003053.pub6 |pmid=29183107|pmc=6486196 |quote=Our updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low. }}</ref> This includes in those who have not been able to get pregnant with clomiphene.<ref>{{cite journal | vauthors = Ghazeeri GS, Nassar AH, Younes Z, Awwad JT | title = Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview | journal = Acta Obstetricia et Gynecologica Scandinavica | volume = 91 | issue = 6 | pages = 658\u201378 | date = June 2012 | pmid = 22375613 | doi = 10.1111/j.1600-0412.2012.01385.x }}</ref> Metformin does not appear to change the risk of miscarriage.<ref name=Mor2017/> A number of other benefits have also been found both during pregnancy and in nonpregnant people with PCOS.<ref>{{cite journal | vauthors = Kumar P, Khan K | title = Effects of metformin use in pregnant patients with polycystic ovary syndrome | journal = Journal of Human Reproductive Sciences | volume = 5 | issue = 2 | pages = 166\u20139 | date = May 2012 | pmid = 23162354 | pmc = 3493830 | doi = 10.4103/0974-1208.101012 }}</ref><ref>{{cite journal |vauthors=Tay CT, Joham AE, Hiam DS, Gadalla MA, Pundir J, Thangaratinam S, Teede HJ, Moran LJ |display-authors=3 |title=Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. |journal=Clinical Endocrinology |date=November 2018 |volume=89 |issue=5 |pages=535\u201353 |doi=10.1111/cen.13753 |pmid=29846959 |doi-access=free }}</ref> In women with PCOS undergoing ''in vitro'' fertilization, evidence does not support a benefit with respect to live births.<ref>{{cite journal |vauthors=Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR |display-authors=3 |title=Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome |journal=Cochrane Database Syst Rev |volume= |issue=11 |pages=CD006105 |date=November 2014 |pmid=25406011 |doi=10.1002/14651858.CD006105.pub3 |pmc=6953331 |url=}}</ref> The evidence does not support general use during pregnancy for improving maternal and infant outcomes in obese women.<ref>{{cite journal |vauthors=Dodd JM, Grivell RM, Deussen AR, Hague WM |display-authors=3 |title=Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes |journal=Cochrane Database Syst Rev |volume=7 |issue= |pages=CD010564 |date=July 2018 |pmid=30039871 |pmc=6513233 |doi=10.1002/14651858.CD010564.pub2 |url=}}</ref>\n\nThe United Kingdom's [[National Institute for Health and Clinical Excellence]] recommended in 2004 that women with PCOS and a [[body mass index]] above 25 be given metformin for [[anovulation]] and [[infertility]] when other therapies fail to produce results.<ref name=\"NICEfertility\">{{cite book | author=National Collaborating Centre for Women's and Children's Health | title=Fertility: assessment and treatment for people with fertility problems | location=London | publisher=Royal College of Obstetricians and Gynaecologists | year=2004 | isbn=978-1-900364-97-3 | pages=58\u201359 | url=http://www.nice.org.uk/nicemedia/pdf/cg011fullguideline.pdf | url-status=live | archive-url=https://web.archive.org/web/20090711000422/http://www.nice.org.uk/nicemedia/pdf/CG011fullguideline.pdf | archive-date=2009-07-11 | df= }}</ref> UK and international [[clinical practice guideline]]s do not recommend metformin as a first-line treatment<ref>{{cite web | vauthors = Balen A |title=Metformin therapy for the management of infertility in women with polycystic ovary syndrome |work=Scientific Advisory Committee Opinion Paper 13 |publisher=Royal College of Obstetricians and Gynaecologists |date=December 2008 |url=http://www.rcog.org.uk/files/rcog-corp/uploaded-files/SAC13metformin-minorrevision.pdf |access-date=2009-12-13 |url-status=dead |archive-url=https://www.webcitation.org/5m73m3kuM?url=http://www.rcog.org.uk/files/rcog-corp/uploaded-files/SAC13metformin-minorrevision.pdf |archive-date=2009-12-18 |df= }}</ref> or do not recommend it at all, except for women with [[glucose intolerance]].<ref name=\"pmid18308833\">{{cite journal | author = The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group | title = Consensus on infertility treatment related to polycystic ovary syndrome | journal = Human Reproduction | volume = 23 | issue = 3 | pages = 462\u201377 | date = March 2008 | pmid = 18308833 | doi = 10.1093/humrep/dem426 | doi-access = free }}</ref> The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from medical treatment. Metformin treatment decreases the risk of developing type 2 diabetes mellitus in women with PCOS who exhibited impaired glucose tolerance (IGT) at baseline.<ref name=\"pmid20840272\"/><ref name=\"pmid19841045\">{{cite journal | vauthors = Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN | title = Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome | journal = European Journal of Endocrinology | volume = 162 | issue = 2 | pages = 193\u2013212 | date = February 2010 | pmid = 19841045 | doi = 10.1530/EJE-09-0733 | doi-access = free }}</ref>\n\n=== Diabetes mellitus and pregnancy ===\nA review of metformin use during pregnancy compared to insulin alone found good short-term safety for both the mother and baby, but unclear long-term safety.<ref>{{cite journal | vauthors = Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L | title = Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis | journal = Diabetic Medicine | volume = 34 | issue = 1 | pages = 27\u201336 | date = January 2017 | pmid = 27150509 | doi = 10.1111/dme.13150 }}</ref> Several [[observational study|observational studies]] and randomized, controlled trials found metformin to be as effective and safe as insulin for the management of gestational diabetes.<ref name=Nicholson>{{cite journal | vauthors = Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E | title = Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review | journal = Obstetrics and Gynecology | volume = 113 | issue = 1 | pages = 193\u2013205 | date = January 2009 | pmid = 19104375 | doi = 10.1097/AOG.0b013e318190a459 }}</ref><ref>{{cite journal | vauthors = Kitwitee P, Limwattananon S, Limwattananon C, Waleekachonlert O, Ratanachotpanich T, Phimphilai M, Nguyen TV, Pongchaiyakul C | title = Metformin for the treatment of gestational diabetes: An updated meta-analysis | journal = Diabetes Research and Clinical Practice | volume = 109 | issue = 3 | pages = 521\u201332 | date = September 2015 | pmid = 26117686 | doi = 10.1016/j.diabres.2015.05.017 }}</ref> Nonetheless, several concerns have been raised and evidence on the long-term safety of metformin for both mother and child is lacking.<ref name=\"Balsells2015\">{{cite journal | vauthors = Balsells M, Garc\u00eda-Patterson A, Sol\u00e0 I, Roqu\u00e9 M, Gich I, Corcoy R | title = Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis | journal = BMJ | volume = 350 | pages = h102 | date = January 2015 | pmid = 25609400 | pmc = 4301599 | doi = 10.1136/bmj.h102 | type = Systematic Review & Meta-Analysis }}</ref> Compared with insulin, women with gestational diabetes treated with metformin gain less weight and are less likely to develop pre\u2010eclampsia during pregnancy.<ref name=\"Balsells2015\" /><ref>{{cite journal |vauthors=Alqudah A, McKinley MC, McNally R, Graham U, Watson CJ, Lyons TJ, McClements L |display-authors=3 |title=Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis |journal=Diabet. Med. |volume=35 |issue=2 |pages=160\u2013172 |date=February 2018 |pmid=29044702 |doi=10.1111/dme.13523 |url=https://pure.qub.ac.uk/portal/en/publications/the-risk-of-preeclampsia-in-women-taking-metformin-systematic-review-and-metaanalysis(8020376c-6e9c-4795-af4b-15441b5773bf).html}}</ref> Babies born to women treated with metformin have less [[visceral fat]], and this may make them less prone to insulin resistance in later life.<ref name=\"SivalingamMyers2014\">{{cite journal | vauthors = Sivalingam VN, Myers J, Nicholas S, Balen AH, Crosbie EJ | title = Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications | journal = Human Reproduction Update | volume = 20 | issue = 6 | pages = 853\u201368 | year = 2014 | pmid = 25013215 | doi = 10.1093/humupd/dmu037 | doi-access = free }}</ref> The use of metformin for gestational diabetes resulted in smaller babies compared to treatment with insulin. However, despite initially lower birth weight, children exposed to metformin during pregnancy had accelerated growth after birth, and were heavier by mid-childhood than those exposed to insulin during pregnancy. This pattern of initial low birth weight followed by catch-up growth that surpasses comparative children has been associated with long-term cardio-metabolic disease.<ref>{{cite journal |vauthors=Tarry-Adkins JL, Aiken CE, Ozanne SE |title=Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis |journal=PLOS Med. |volume=16 |issue=8 |pages=e1002848 |date=August 2019 |pmid=31386659 |pmc=6684046 |doi=10.1371/journal.pmed.1002848 |url=}}</ref>\n\n=== Weight change===\nMetformin is typically associated with weight loss.<ref>{{cite journal |vauthors=Yerevanian A, Soukas AA |title=Metformin: Mechanisms in Human Obesity and Weight Loss |journal=Current Obesity Reports |date=June 2019 |volume=8 |issue=2 |pages=156\u201364 |doi=10.1007/s13679-019-00335-3 |pmid=30874963|pmc=6520185 }}</ref> Metformin appears to be safe and effective in counteracting  the weight gain caused by the [[antipsychotic]] medications [[olanzapine]] and [[clozapine]].<ref name=Choi2015>{{cite journal | vauthors = Choi YJ | title = Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis | journal = TheScientificWorldJournal | volume = 2015 | pages = 1\u201310 | year = 2015 | pmid = 25664341 | pmc = 4310265 | doi = 10.1155/2015/970730 }}</ref><ref name=PraharajJana2011>{{cite journal | vauthors = Praharaj SK, Jana AK, Goyal N, Sinha VK | title = Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis | journal = British Journal of Clinical Pharmacology | volume = 71 | issue = 3 | pages = 377\u201382 | date = March 2011 | pmid = 21284696 | pmc = 3045546 | doi = 10.1111/j.1365-2125.2010.03783.x }}</ref> Although modest reversal of clozapine-associated weight gain is found with metformin, primary prevention of weight gain is more valuable.<ref name=HolscherSiskind2016>{{cite journal | vauthors = Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S | title = Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis | journal = PLOS One | volume = 11 | issue = 6 | pages = e0156208 | year = 2016 | pmid = 27304831 | pmc = 4909277 | doi = 10.1371/journal.pone.0156208 | bibcode = 2016PLoSO..1156208S }}</ref>\n\n===Use with insulin===\nMetformin may reduce the insulin requirement in [[Diabetes mellitus type 1|type 1 diabetes]], albeit with an increased risk of hypoglycemia.<ref name=\":0\">{{cite journal | vauthors = Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR | title = The use of metformin in type 1 diabetes: a systematic review of efficacy | journal = Diabetologia | volume = 53 | issue = 5 | pages = 809\u201320 | date = May 2010 | pmid = 20057994 | doi = 10.1007/s00125-009-1636-9 | doi-access = free }}</ref>\n\n== Contraindications ==\nThe FDA revised its [[package insert|prescribing information]] on metformin in 2016.<ref name=\"FDA Safety\" />{{update inline|date=February 2020}}\n\nMetformin is [[contraindication|contraindicated]] in people with:\n* severe renal impairment (estimated [[Renal function|glomerular filtration rate]] (eGFR) below 30 ml/min/1.73 m2)\n* known hypersensitivity to metformin\n* acute or chronic [[metabolic acidosis]], including [[diabetic ketoacidosis]], with or without [[coma]]\n\nWarnings are also given regarding the use of metformin in less severe renal impairment, people aged 65 years old or greater,  [[Hypoxia (medical)|hypoxic]] states (e.g., [[Heart failure|acute congestive heart failure)]], excessive alcohol intake, [[Liver disease|hepatic impairment]], concomitant use of certain drugs (e.g. [[carbonic anhydrase inhibitor]]s such as [[topiramate]]), surgery, and other procedures, or in people having a radiological study with administration of an [[iodine|iodinated]] [[radiocontrast|contrast]] agent.\n\nMetformin is recommended to be temporarily discontinued before any procedure involving use of iodinated contrast agents, (such as a contrast-enhanced [[computed tomography|CT scan]] or [[angiogram]]) due to the increased risk of lactic acidosis resulting from impaired kidney function;<ref name=\"RCR\">Weir J (19 March 1999). [https://web.archive.org/web/20040104141219/http://www.rcr.ac.uk/pubtop.asp?PublicationID=70 Guidelines with Regard to Metformin-Induced Lactic Acidosis and X-ray Contrast Medium Agents]. [[Royal College of Radiologists]]. Retrieved 26 October 2007 through the [[Internet Archive]].</ref><ref name=\"ESUR\">{{cite journal | vauthors = Thomsen HS, Morcos SK | title = Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines | journal = The British Journal of Radiology | volume = 76 | issue = 908 | pages = 513\u20138 | date = August 2003 | pmid = 12893691 | doi = 10.1259/bjr/26964464 }}</ref> metformin can be resumed after two days after contrast administration, if renal function is adequate and stable.\n\n== Adverse effects ==\nThe most common [[adverse drug reaction|adverse effect]] of metformin is gastrointestinal irritation, including [[diarrhea]], cramps, nausea, vomiting, and increased [[flatulence]]; metformin is more commonly associated with gastrointestinal side effects than most other antidiabetic medications.<ref name=Bolen>{{cite journal | vauthors = Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL | title = Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus | journal = Annals of Internal Medicine | volume = 147 | issue = 6 | pages = 386\u201399 | date = September 2007 | pmid = 17638715 | doi = 10.7326/0003-4819-147-6-200709180-00178 | doi-access = free }}</ref> The most serious potential side effect of metformin use is [[lactic acidosis]]; this complication is very rare, and the vast majority of these cases seem to be related to comorbid conditions, such as impaired liver or kidney function, rather than to the metformin itself.<ref>{{cite journal | vauthors = Khurana R, Malik IS | title = Metformin: safety in cardiac patients | journal = Heart | volume = 96 | issue = 2 | pages = 99\u2013102 | date = January 2010 | pmid = 19564648 | doi = 10.1136/hrt.2009.173773 }}</ref>\n\n=== Gastrointestinal ===\nGastrointestinal upset can cause severe discomfort; it is most common when metformin is first administered, or when the dose is increased. The discomfort can often be avoided by beginning at a low dose (1.0 to 1.7&nbsp;grams per day) and increasing the dose gradually, but even with low doses, 5% of people may be unable to tolerate metformin.<ref name=\":1\">{{cite journal | vauthors = Fujita Y, Inagaki N | title = Metformin: New Preparations and Nonglycemic Benefits | journal = Current Diabetes Reports | volume = 17 | issue = 1 | pages = 5 | date = January 2017 | pmid = 28116648 | doi = 10.1007/s11892-017-0829-8 }}</ref> Use of slow- or extended-release preparations may improve tolerability.<ref name=\":1\" />\n\nLong-term use of metformin has been associated with increased [[homocysteine]] levels<ref name=Wulffele>{{cite journal | vauthors = Wulffel\u00e9 MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD | title = Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial | journal = Journal of Internal Medicine | volume = 254 | issue = 5 | pages = 455\u201363 | date = November 2003 | pmid = 14535967 | doi = 10.1046/j.1365-2796.2003.01213.x | url = https://semanticscholar.org/paper/214429d3c5eadc51e1ee7d70f080b4c5a1f1087d }}</ref> and [[malabsorption]] of [[cyanocobalamin|vitamin B<sub>12</sub>]].<ref name = Andres>{{cite journal | vauthors = Andr\u00e8s E, Noel E, Goichot B | title = Metformin-associated vitamin B12 deficiency | journal = Archives of Internal Medicine | volume = 162 | issue = 19 | pages = 2251\u20132 | date = October 2002 | pmid = 12390080 | doi = 10.1001/archinte.162.19.2251-a }}</ref><ref name = Gilligan>{{cite journal | vauthors = Gilligan MA | title = Metformin and vitamin B12 deficiency | journal = Archives of Internal Medicine | volume = 162 | issue = 4 | pages = 484\u20135 | date = February 2002 | pmid = 11863489 | doi = 10.1001/archinte.162.4.484 }}</ref> Higher doses and prolonged use are associated with increased incidence of [[Vitamin B12 deficiency|vitamin B<sub>12</sub> deficiency]],<ref>{{cite journal | vauthors = de Jager J, Kooy A, Lehert P, Wulffel\u00e9 MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD | title = Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial | journal = BMJ | volume = 340 | pages = c2181 | date = May 2010 | pmid = 20488910 | pmc = 2874129 | doi = 10.1136/bmj.c2181 }}</ref> and some researchers recommend screening or prevention strategies.<ref>{{cite journal | vauthors = Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM | title = Risk factors of vitamin B(12) deficiency in patients receiving metformin | journal = Archives of Internal Medicine | volume = 166 | issue = 18 | pages = 1975\u20139 | date = October 2006 | pmid = 17030830 | doi = 10.1001/archinte.166.18.1975 | doi-access = free }}</ref>\n\n=== Lactic acidosis ===\n[[Lactic acidosis]] almost never occurs with metformin exposure during routine medical care.<ref>{{cite journal |vauthors=Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B |display-authors=3 |title=Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes |journal=Diabetologia |volume=52 |issue=1 |pages=17\u201330 |date=January 2009 |pmid=18941734 |doi=10.1007/s00125-008-1157-y |url=|doi-access=free }}</ref> Rates of metformin-associated lactic acidosis is about nine per 100,000 person-years, which is similar to the background rate of lactic acidosis in the general population.<ref name=\"Stang\">{{cite journal | vauthors = Stang M, Wysowski DK, Butler-Jones D | title = Incidence of lactic acidosis in metformin users | journal = Diabetes Care | volume = 22 | issue = 6 | pages = 925\u20137 | date = June 1999 | pmid = 10372243 | doi = 10.2337/diacare.22.6.925 }}</ref> A systematic review concluded no data exists to definitively link metformin to lactic acidosis.<ref name=Salpeter>{{cite journal | vauthors = Salpeter SR, Greyber E, Pasternak GA, Salpeter EE | title = Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis | journal = Archives of Internal Medicine | volume = 163 | issue = 21 | pages = 2594\u2013602 | date = November 2003 | pmid = 14638559 | doi = 10.1001/archinte.163.21.2594 | doi-access = free }}</ref>\n\nMetformin is generally safe in people with mild to moderate chronic kidney disease, with proportional reduction of metformin dose according to severity of estimated glomerular filtration rate and with periodic assessment of kidney function, (e.g., periodic plasma creatinine measurement).<ref>{{cite journal |vauthors=Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK |display-authors=3 |title=Metformin in patients with type 2 diabetes and kidney disease: a systematic review |journal=JAMA |volume=312 |issue=24 |pages=2668\u201375 |date=2014 |pmid=25536258 |pmc=4427053 |doi=10.1001/jama.2014.15298 |url=}}</ref> The [[FDA]] recommends avoiding the use of metformin in more severe chronic kidney disease, below the [[estimated glomerular filtration rate]] (eGFR) cutoff of 30 mL/minute/1.73 m<sup>2</sup>.<ref name=\"FDA Safety\">{{cite web |title=FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function |url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain |website=U.S. [[Food and Drug Administration]] (FDA) |accessdate=21 December 2018 |date=14 November 2017 }}</ref> Lactate uptake by the liver is diminished with metformin use because lactate is a [[Substrate (biochemistry)|substrate]] for hepatic [[gluconeogenesis]], a process that metformin inhibits. In healthy individuals, this slight excess is cleared by other mechanisms (including uptake by unimpaired kidneys), and no significant elevation in blood levels of lactate occurs.<ref name=Umesh>{{cite book |vauthors=Maharani U |veditors=Papadakis MA, McPhee SJ |chapter=Chapter 27: Diabetes Mellitus & Hypoglycemia |title=Current Medical Diagnosis and Treatment 2010 |edition=49th |publisher=McGraw-Hill Medical |location= |year=2009 |pages=[https://archive.org/details/isbn_9780071624442/page/1092 1092\u201393] |isbn=978-0-07-162444-2 |url-access=registration |url=https://archive.org/details/isbn_9780071624442/page/1092 }}</ref> Given severely-impaired kidney function, clearance of metformin and lactate is reduced, increasing levels of both, and possibly causing lactic acid buildup. Because metformin decreases liver uptake of lactate, any condition that may precipitate lactic acidosis is a contraindication. Common causes include [[alcoholism]] (due to depletion of [[nicotinamide adenine dinucleotide|NAD+]] stores), heart failure and respiratory disease (due to inadequate tissue oxygenation); the most common cause is kidney disease.<ref name=Golan>{{cite book | vauthors = Shu AD, Myers MG, Shoelson SE | veditors = Golan ED, Tashjian AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS | chapter=Chapter 29: Pharmacology of the Endocrine Pancreas |title=Principles of pharmacology: the pathophysiologic basis of drug therapy |publisher=Lippincott, Williams & Wilkins |location=Philadelphia |year=2005 |pages=540\u201341 |isbn=978-0-7817-4678-6}}</ref>\n\nMetformin has been suggested as increasing production of lactate in the large intestine, which could potentially contribute to lactic acidosis in those with risk factors.<ref name=Kirpichnikov>{{cite journal | vauthors = Kirpichnikov D, McFarlane SI, Sowers JR | title = Metformin: an update | journal = Annals of Internal Medicine | volume = 137 | issue = 1 | pages = 25\u201333 | date = July 2002 | pmid = 12093242 | doi = 10.7326/0003-4819-137-1-200207020-00009 }}</ref> However, the clinical significance of this is unknown, and the risk of metformin-associated lactic acidosis is most commonly attributed to decreased hepatic uptake rather than increased intestinal production.<ref name=Umesh /><ref name=Golan /><ref>{{cite book | vauthors = Davis SN | veditors = Brunton L, Lazo J, Parker K |title=Goodman & Gilman's The Pharmacological Basis of Therapeutics |edition=11th |year=2006 |publisher=[[McGraw-Hill]] |location=New York |isbn=978-0-07-142280-2 |pages= |chapter=Chapter 60: Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the Endocrine Pancreas| title-link = Goodman & Gilman's The Pharmacological Basis of Therapeutics }}</ref>\n\nThe risk of metformin-associated lactic acidosis is also increased by massive overdose of metformin, although even quite large doses are often not fatal.<ref name=\"Teale\">{{cite journal | vauthors = Teale KF, Devine A, Stewart H, Harper NJ | title = The management of metformin overdose | journal = Anaesthesia | volume = 53 | issue = 7 | pages = 698\u2013701 | date = July 1998 | pmid = 9771180 | doi = 10.1046/j.1365-2044.1998.436-az0549.x }}</ref>\n\n=== Overdose ===\nThe most common symptoms following overdose include vomiting, [[diarrhea]], abdominal pain, [[tachycardia]], drowsiness, and, rarely, [[hypoglycemia]] or [[hyperglycemia]].<ref name=\"Forrester\">{{cite journal | vauthors = Forrester MB | title = Adult metformin ingestions reported to Texas poison control centers, 2000-2006 | journal = Human & Experimental Toxicology | volume = 27 | issue = 7 | pages = 575\u201383 | date = July 2008 | pmid = 18829734 | doi = 10.1177/0960327108090589 | citeseerx = 10.1.1.1031.9486 }}</ref><ref name=\"Suchard\">{{cite journal | vauthors = Suchard JR, Grotsky TA | title = Fatal metformin overdose presenting with progressive hyperglycemia | journal = The Western Journal of Emergency Medicine | volume = 9 | issue = 3 | pages = 160\u20134 | date = August 2008 | pmid = 19561734 | pmc = 2672258 }}</ref>  Treatment of metformin overdose is generally supportive, as no specific antidote is known. Extracorporeal treatments are recommended in severe overdoses.<ref name=Cal2015>{{cite journal | vauthors = Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, Hoffman RS, Nolin TD, Ghannoum M | title = Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup | journal = Critical Care Medicine | volume = 43 | issue = 8 | pages = 1716\u201330 | date = August 2015 | pmid = 25860205 | doi = 10.1097/CCM.0000000000001002 }}</ref> Due to metformin's low [[molecular weight]] and lack of [[plasma protein binding]], these techniques have the benefit of removing metformin from [[blood plasma]], preventing further lactate overproduction.<ref name=Cal2015 />\n\nMetformin may be quantified in blood, plasma, or serum to monitor therapy, confirm a diagnosis of poisoning, or assist in a forensic death investigation. Blood or plasma metformin concentrations are usually in a range of 1\u20134&nbsp;mg/l in persons receiving therapeutic doses, 40\u2013120&nbsp;mg/l in victims of acute overdosage, and 80\u2013200&nbsp;mg/l in fatalities. Chromatographic techniques are commonly employed.<ref>{{cite journal | vauthors = Liu A, Coleman SP | title = Determination of metformin in human plasma using hydrophilic interaction liquid chromatography-tandem mass spectrometry | journal = Journal of Chromatography B | volume = 877 | issue = 29 | pages = 3695\u2013700 | date = November 2009 | pmid = 19783231 | doi = 10.1016/j.jchromb.2009.09.020 }}</ref><ref>R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 939\u2013940.</ref>\n\n=== Interactions ===\nThe [[H2 antagonist|H<sub>2</sub>-receptor antagonist]] [[cimetidine]] causes an increase in the plasma concentration of metformin by reducing [[clearance (medicine)|clearance]] of metformin by the kidneys;<ref>{{cite journal | vauthors = Somogyi A, Stockley C, Keal J, Rolan P, Bochner F | title = Reduction of metformin renal tubular secretion by cimetidine in man | journal = British Journal of Clinical Pharmacology | volume = 23 | issue = 5 | pages = 545\u201351 | date = May 1987 | pmid = 3593625 | pmc = 1386190 | doi = 10.1111/j.1365-2125.1987.tb03090.x }}</ref> both metformin and cimetidine are cleared from the body by [[Renal physiology#Secretion|tubular secretion]], and both, particularly the [[cation]]ic (positively [[electric charge|charged]]) form of cimetidine, may compete for the same transport mechanism.<ref name=PI /> A small [[blind experiment|double-blind]], randomized study found the [[antibiotic]] [[cephalexin]] to also increase metformin concentrations by a similar mechanism;<ref>{{cite journal | vauthors = Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y | title = Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers | journal = Drug Metabolism and Drug Interactions | volume = 19 | issue = 1 | pages = 41\u20138 | year = 2002 | pmid = 12222753 | doi = 10.1515/dmdi.2002.19.1.41 }}</ref> theoretically, other cationic medications may produce the same effect.<ref name=PI />\n\nMetformin also interacts with [[anticholinergic]] medications, due to their effect on gastric motility. Anticholinergic drugs reduce gastric motility, prolonging the time drugs spend in the [[gastrointestinal tract]]. This impairment may lead to more metformin being absorbed than without the presence of an anticholinergic drug, thereby increasing the concentration of metformin in the plasma and increasing the risk for adverse effects.<ref name=\"May DDI Review\">{{cite journal | vauthors = May M, Schindler C | title = Clinically and pharmacologically relevant interactions of antidiabetic drugs | journal = Therapeutic Advances in Endocrinology and Metabolism | volume = 7 | issue = 2 | pages = 69\u201383 | date = April 2016 | pmid = 27092232 | pmc = 4821002 | doi = 10.1177/2042018816638050 }}</ref>\n\n== Pharmacology ==\n\n=== Mechanism of action ===\nThe molecular mechanism of metformin is not completely understood. Multiple potential mechanisms of action have been proposed: inhibition of the mitochondrial respiratory chain (complex I), activation of [[AMP-activated protein kinase]] (AMPK), inhibition of glucagon-induced elevation of [[cyclic adenosine monophosphate]] (cAMP) with reduced activation of [[protein kinase A]] (PKA), inhibition of mitochondrial [[Glycerol-3-phosphate dehydrogenase|glycerophosphate dehydrogenase]], and an effect on [[gut flora|gut microbiota]].<ref name=\"Rena_2013\">{{cite journal | vauthors = Rena G, Pearson ER, Sakamoto K | title = Molecular mechanism of action of metformin: old or new insights? | journal = Diabetologia | volume = 56 | issue = 9 | pages = 1898\u2013906 | date = September 2013 | pmid = 23835523 | pmc = 3737434 | doi = 10.1007/s00125-013-2991-0 }}</ref><ref name =\"Burcelin\">{{cite journal | vauthors = Burcelin R | title = The antidiabetic gutsy role of metformin uncovered? | journal = Gut | volume = 63 | issue = 5 | pages = 706\u20137 | date = May 2014 | pmid = 23840042 | doi = 10.1136/gutjnl-2013-305370 }}</ref><ref>{{cite journal | vauthors = Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI | title = Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase | journal = Nature | volume = 510 | issue = 7506 | pages = 542\u20136 | date = June 2014 | pmid = 24847880 | pmc = 4074244 | doi = 10.1038/nature13270 | bibcode = 2014Natur.510..542M }}</ref> Ultimately, it decreases [[gluconeogenesis]] (glucose production) in the liver.<ref name=Kirpichnikov /><ref name=\"pmid26680745\">{{cite journal | vauthors=Triggle CR, Ding H | title=Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium | journal= [[Acta Physiologica]] | volume=219 | issue=1 | pages=138\u2013151 | year=2017 | doi= 10.1111/apha.12644 | pmid = 26680745}}</ref>  It also has an insulin-sensitizing effect with multiple actions on tissues including the liver, skeletal muscle, endothelium, adipose tissue, and the ovary.<ref name=\"pmid20840272\">{{cite journal | vauthors = Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C | title = Metformin in polycystic ovary syndrome | journal = Annals of the New York Academy of Sciences | volume = 1205 | issue = 1 | pages = 192\u20138 | date = September 2010 | pmid = 20840272 | doi = 10.1111/j.1749-6632.2010.05679.x | bibcode = 2010NYASA1205..192D }}</ref><ref name=\"pmid14576245\">{{cite journal | vauthors = Lord JM, Flight IH, Norman RJ | title = Metformin in polycystic ovary syndrome: systematic review and meta-analysis | journal = BMJ | volume = 327 | issue = 7421 | pages = 951\u20133 | date = October 2003 | pmid = 14576245 | doi = 10.1136/bmj.327.7421.951 | pmc = 259161 }}</ref> The average patient with type 2 diabetes has three times the normal rate of gluconeogenesis; metformin treatment reduces this by over one-third.<ref name=Hundal>{{cite journal | vauthors = Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI | title = Mechanism by which metformin reduces glucose production in type 2 diabetes | journal = Diabetes | volume = 49 | issue = 12 | pages = 2063\u20139 | date = December 2000 | pmid = 11118008 | pmc = 2995498 | doi = 10.2337/diabetes.49.12.2063 }}</ref>\n\nActivation of [[AMPK]] was required for metformin's inhibitory effect on liver glucose production.<ref name=\"Zhou\">{{cite journal | vauthors = Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE | title = Role of AMP-activated protein kinase in mechanism of metformin action | journal = The Journal of Clinical Investigation | volume = 108 | issue = 8 | pages = 1167\u201374 | date = October 2001 | pmid = 11602624 | pmc = 209533 | doi = 10.1172/JCI13505 }}</ref> AMPK is an enzyme that plays an important role in insulin signalling, whole body energy balance and the metabolism of glucose and [[lipid|fats]].<ref>{{cite journal | vauthors = Towler MC, Hardie DG | title = AMP-activated protein kinase in metabolic control and insulin signaling | journal = Circulation Research | volume = 100 | issue = 3 | pages = 328\u201341 | date = February 2007 | pmid = 17307971 | doi = 10.1161/01.RES.0000256090.42690.05 | doi-access = free }}</ref> AMPK Activation was required for an increase in the expression of [[small heterodimer partner]], which in turn inhibited the [[gene expression|expression]] of the hepatic gluconeogenic genes [[phosphoenolpyruvate carboxykinase]] and [[glucose 6-phosphatase]].<ref>{{cite journal | vauthors = Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK, Lee CH, Choi HS | title = Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP | journal = Diabetes | volume = 57 | issue = 2 | pages = 306\u201314 | date = February 2008 | pmid = 17909097 | doi = 10.2337/db07-0381 | doi-access = free }}</ref> Metformin is frequently used in research along with [[AICA ribonucleotide]] as an AMPK agonist.  The mechanism by which biguanides increase the activity of AMPK remains uncertain; however, metformin increases the concentration of [[cytosol]]ic [[adenosine monophosphate]] (AMP) (as opposed to a change in total AMP or total AMP/[[adenosine triphosphate]]).<ref>{{cite journal | vauthors = Zhang L, He H, Balschi JA | title = Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration | journal = American Journal of Physiology. Heart and Circulatory Physiology | volume = 293 | issue = 1 | pages = H457\u201366 | date = July 2007 | pmid = 17369473 | doi = 10.1152/ajpheart.00002.2007 }}</ref> Increased cellular AMP has been proposed to explain the inhibition of glucagon-induced increase in cAMP and activation of PKA.<ref name=\"Rena_2013\" /> Metformin and other biguanides may antagonize the action of [[glucagon]], thus reducing fasting glucose levels.<ref name=\"Miller2013\">{{cite journal | vauthors = Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ | title = Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP | journal = Nature | volume = 494 | issue = 7436 | pages = 256\u201360 | date = February 2013 | pmid = 23292513 | pmc = 3573218 | doi = 10.1038/nature11808 | bibcode = 2013Natur.494..256M }}</ref> Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice and this may contribute to its mode of action possibly through an effect on [[glucagon-like peptide-1]] secretion.<ref name=\"Burcelin\" />\n\nIn addition to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances peripheral [[glucose uptake]] (by inducing the phosphorylation of [[GLUT4]] enhancer factor), decreases insulin-induced suppression of [[fatty acid metabolism|fatty acid oxidation]],<ref name=Collier>{{cite journal | vauthors = Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ | title = Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle | journal = American Journal of Physiology. Endocrinology and Metabolism | volume = 291 | issue = 1 | pages = E182\u20139 | date = July 2006 | pmid = 16478780 | doi = 10.1152/ajpendo.00272.2005 }}</ref> and decreases absorption of glucose from the [[gastrointestinal tract]]. Increased peripheral use of glucose may be due to improved insulin binding to insulin receptors.<ref>{{cite journal | vauthors = Bailey CJ, Turner RC | title = Metformin | journal = The New England Journal of Medicine | volume = 334 | issue = 9 | pages = 574\u20139 | date = February 1996 | pmid = 8569826 | doi = 10.1056/NEJM199602293340906 }}</ref> The increase in insulin binding after metformin treatment has also been demonstrated in patients with [[Diabetes mellitus type 2|NIDDM]].<ref>{{cite journal | vauthors = Fantus IG, Brosseau R | title = Mechanism of action of metformin: insulin receptor and postreceptor effects in vitro and in vivo | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 63 | issue = 4 | pages = 898\u2013905 | date = October 1986 | pmid = 3745404 | doi = 10.1210/jcem-63-4-898 }}</ref>\n\nAMPK probably also plays a role in increased peripheral insulin sensitivity, as metformin administration increases AMPK activity in skeletal muscle.<ref>{{cite journal | vauthors = Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ | title = Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes | journal = Diabetes | volume = 51 | issue = 7 | pages = 2074\u201381 | date = July 2002 | pmid = 12086935 | doi = 10.2337/diabetes.51.7.2074 | doi-access = free }}</ref> AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in insulin-independent glucose uptake. Some metabolic actions of metformin do appear to occur by AMPK-independent mechanisms.\n\nMetformin has indirect [[antiandrogen]]ic effects in women with [[insulin resistance]], such as those with [[polycystic ovary syndrome]], due to its beneficial effects on insulin sensitivity.<ref name=\"NikolakisKyrgidis2019\">{{cite journal|vauthors=Nikolakis G, Kyrgidis A, Zouboulis CC |title=Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data|journal=American Journal of Clinical Dermatology|volume=20|issue=4|year=2019|pages=503\u201313|issn=1175-0561|doi=10.1007/s40257-019-00442-w|pmid=31073704 }}</ref> It may reduce [[testosterone]] levels in such women by 50%.<ref name=\"NikolakisKyrgidis2019\" />\n\n=== Pharmacokinetics ===\nMetformin has an oral [[bioavailability]] of 50\u201360% under [[fasting]] conditions, and is absorbed slowly.<ref name=PI>{{cite web |author=Bristol-Myers Squibb |author-link=Bristol-Myers Squibb |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf |title=Glucophage (metformin hydrochloride tablets) Label Information |date=27 August 2008 |access-date=2009-12-08 |publisher=U.S. Food and Drug Administration |url-status=live |archive-url=https://web.archive.org/web/20100922233241/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf |archive-date=22 September 2010 |df= }}</ref><ref name=Heller>{{cite journal | vauthors = Heller JB |title=Metformin overdose in dogs and cats |journal=Veterinary Medicine |issue=April |year=2007 |pages=231\u201333 |url=http://www.aspca.org/site/DocServer/vetm0407_231-234.pdf?docID=11061 |url-status=dead |archive-url=https://web.archive.org/web/20071023063354/http://www.aspca.org/site/DocServer/vetm0407_231-234.pdf?docID=11061 |archive-date=2007-10-23 |df= }}</ref> Peak plasma concentrations (C<sub>max</sub>) are reached within one to three hours of taking immediate-release metformin and four to eight hours with extended-release formulations.<ref name=PI /><ref name = Heller /> The [[plasma protein binding]] of metformin is negligible, as reflected by its very high [[volume of distribution|apparent volume of distribution]] (300\u20131000&nbsp;l after a single dose). [[Steady state]] is usually reached in one or two days.<ref name=PI />\n\nMetformin has acid dissociation constant values (pK<sup>a</sup>) of 2.8 and 11.5, so exists very largely as the hydrophilic cationic species at physiological pH values. The metformin pK<sup>a</sup> values make it a stronger base than most other basic medications with less than 0.01% nonionized in blood. Furthermore, the [[Lipophilicity|lipid solubility]] of the nonionized species is slight as shown by its low logP value (log(10) of the distribution coefficient of the nonionized form between octanol and water) of \u22121.43. These chemical parameters indicate low lipophilicity and, consequently, rapid passive diffusion of metformin through cell membranes is unlikely. As a result of its low lipid solubility it requires the [[Membrane transport protein|transporter]] [[SLC22A1]] in order for it to enter cells.<ref>{{cite journal | vauthors = Rosilio C, Ben-Sahra I, Bost F, Peyron JF | title = Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia | journal = Cancer Letters | volume = 346 | issue = 2 | pages = 188\u201396 | date = May 2014 | pmid = 24462823 | doi = 10.1016/j.canlet.2014.01.006 }}</ref><ref name=Pry2015>{{cite journal | vauthors = Pryor R, Cabreiro F | title = Repurposing metformin: an old drug with new tricks in its binding pockets | journal = The Biochemical Journal | volume = 471 | issue = 3 | pages = 307\u201322 | date = November 2015 | pmid = 26475449 | pmc = 4613459 | doi = 10.1042/bj20150497 }}</ref> The logP of metformin is less than that of [[phenformin]] (\u22120.84) because two methyl substituents on metformin impart lesser lipophilicity than the larger phenylethyl side chain in [[phenformin]]. More lipophilic derivatives of metformin are presently under investigation with the aim of producing prodrugs with superior oral absorption than metformin.<ref>{{cite journal | vauthors = Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM | title = Clinical pharmacokinetics of metformin | journal = Clinical Pharmacokinetics | volume = 50 | issue = 2 | pages = 81\u201398 | date = February 2011 | pmid = 21241070 | doi = 10.2165/11534750-000000000-00000 }}</ref>\n\nMetformin is not [[drug metabolism|metabolized]]. It is [[clearance (medicine)|cleared]] from the body by [[renal physiology#Secretion|tubular secretion]] and excreted unchanged in the urine; metformin is undetectable in blood plasma within 24 hours of a single oral dose.<ref name=PI /><ref name=Robert /> The average [[biological half-life|elimination half-life]] in plasma is 6.2 hours.<ref name=PI /> Metformin is distributed to (and appears to accumulate in) [[red blood cell]]s, with a much longer elimination half-life: 17.6 hours<ref name=PI /> (reported as ranging from 18.5 to 31.5 hours in a single-dose study of nondiabetics).<ref name=Robert>{{cite journal | vauthors = Robert F, Fendri S, Hary L, Lacroix C, Andr\u00e9jak M, Lalau JD | title = Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects | journal = Diabetes & Metabolism | volume = 29 | issue = 3 | pages = 279\u201383 | date = June 2003 | pmid = 12909816 | doi = 10.1016/s1262-3636(07)70037-x }}</ref>\n\n== Chemistry ==\nMetformin hydrochloride (1,1-dimethylbiguanide hydrochloride) is freely-soluble in water, slightly soluble in ethanol, but almost insoluble in acetone, ether, or chloroform. The pK<sub>a</sub> of metformin is 12.4.<ref>{{cite book |doi = 10.1002/0471266949.bmc198|chapter = Diabetes Drugs: Present and Emerging|title = Burger's Medicinal Chemistry and Drug Discovery|year = 2010|last1 = Tilley|first1 = Jefferson|last2 = Grimsby|first2 = Joseph|last3 = Erickson|first3 = Shawn|last4 = Berthel|first4 = Steven|isbn = 978-0471266945}}</ref> The usual [[chemical synthesis|synthesis]] of metformin, originally described in 1922, involves the one-pot reaction of [[dimethylamine]] [[hydrochloride]] and [[2-cyanoguanidine]] over heat.<ref name = werner /><ref>{{cite journal | vauthors = Shapiro SL, Parrino VA, Freedman L |title=Hypoglycemic Agents. I Chemical Properties of \u03b2-Phenethylbiguanide. A New Hypoglycemic Agent |journal=[[J Am Chem Soc]] |volume=81 |issue=9 |year=1959 |pages=2220\u201325 |doi=10.1021/ja01518a052}}</ref>\n\n[[File:Metformin synthesis.svg|center|300px]]\n\nAccording to the procedure described in the 1975 Aron patent,<ref>{{cite journal |title=Proc\u00e9d\u00e9 de pr\u00e9paration de chlorhydrate de dim\u00e9thylbiguanide |journal=Patent FR 2322860|language=French|year=1975}}</ref> and the ''Pharmaceutical Manufacturing Encyclopedia'',<ref name=\"isbn0-8155-1526-X\">{{cite book |title=Pharmaceutical Manufacturing Encyclopedia (Sittig's Pharmaceutical Manufacturing Encyclopedia) |edition=3rd |volume=3 |publisher=William Andrew |location=Norwich, NY |year=2007 |page=2208 |isbn=978-0-8155-1526-5}}</ref> [[equivalent weight|equimolar]] amounts of dimethylamine and 2-cyanoguanidine are dissolved in [[toluene]] with cooling to make a [[Concentration#Qualitative description|concentrated]] solution, and an equimolar amount of [[hydrogen chloride]] is slowly added. The mixture begins to boil on its own, and after cooling, metformin hydrochloride [[precipitate]]s with a 96% [[Yield (chemistry)|yield]].\n\n== History ==\n[[File:Galega officinalis1UME.jpg|right|thumb|''Galega officinalis'', a natural source of galegine]]\n\nThe [[biguanide]] class of antidiabetic medications, which also includes the withdrawn agents [[phenformin]] and [[buformin]], originates from the [[Galega officinalis|French lilac]] or goat's rue (''Galega officinalis''), a plant used in folk medicine for several centuries.<ref name=Witters>{{cite journal | vauthors = Witters LA | title = The blooming of the French lilac | journal = The Journal of Clinical Investigation | volume = 108 | issue = 8 | pages = 1105\u20137 | date = October 2001 | pmid = 11602616 | pmc = 209536 | doi = 10.1172/JCI14178 }}</ref> ''Galega officinalis'' itself does not contain any of these medications, but isoamylene guanidine; phenformin, buformin, and metformin are chemically synthesized compounds composed of two guanidine molecules, and are more [[lipophilic]] than the plant-derived parent compound.<ref name=Witters/>\n\nMetformin was first described in the scientific literature in 1922, by Emil Werner and James Bell, as a product in the synthesis of ''N'',''N''-dimethylguanidine.<ref name = werner>{{cite journal | vauthors = Werner E, Bell J | title =The preparation of methylguanidine, and of \u03b2\u03b2-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides respectively |journal=J. Chem. Soc., Trans.|volume=121|pages=1790\u201395 |year=1922 |doi=10.1039/CT9222101790}}</ref> In 1929, Slotta and Tschesche discovered its sugar-lowering action in rabbits, finding it the most potent biguanide analog they studied.<ref name = slotta>See Chemical Abstracts, v.23, 42772 (1929) {{cite journal | vauthors = Slotta KH, Tschesche R|title= \u00dcber Biguanide, II.: Die blutzucker-senkende Wirkung der Biguanide|journal= Berichte der Deutschen Chemischen Gesellschaft (A and B Series)|volume=62|issue= 6|pages=1398\u20131405 |year=1929 |doi=10.1002/cber.19290620605}}</ref> This result was completely forgotten, as other [[guanidine]] analogs, such as the [[synthalin]]s, took over and were themselves soon overshadowed by insulin.<ref name= fifty>{{cite journal | veditors = Campbell IW |title=Metformin&nbsp;\u2013 life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007|journal=The British Journal of Diabetes & Vascular Disease|volume=7|issue=5|pages=247\u201352 |date=September 2007|doi=10.1177/14746514070070051001 }}</ref>\n\nInterest in metformin resumed at the end of the 1940s. In 1950, metformin, unlike some other similar compounds, was found not to decrease [[blood pressure]] and [[heart rate]] in animals.<ref name=\"pmid15405470\">{{cite journal | vauthors = Dawes GS, Mott JC | title = Circulatory and respiratory reflexes caused by aromatic guanidines | journal = British Journal of Pharmacology and Chemotherapy | volume = 5 | issue = 1 | pages = 65\u201376 | date = March 1950 | pmid = 15405470 | pmc = 1509951 | doi = 10.1111/j.1476-5381.1950.tb00578.x }}</ref> That year, Filipino physician Eusebio Y. Garcia<ref>About Eusebio Y. Garcia, see: {{cite web |url=http://sntpost.stii.dost.gov.ph/frames/aprtojun05/Search_for_DOST_NRCP_13to14.htm |title=Search for DOST-NRCP Dr. Eusebio Y. Garcia Award |vauthors=Carteciano J |date=2005 |publisher=Philippines Department of Science and Technology |access-date=2009-12-05 |url-status=dead |archive-url=https://web.archive.org/web/20091024075832/http://sntpost.stii.dost.gov.ph/frames/aprtojun05/Search_for_DOST_NRCP_13to14.htm |archive-date=24 October 2009 |df= }}</ref> used metformin (he named it Fluamine) to treat influenza; he noted the medication \"lowered the blood sugar to minimum physiological limit\" and was not toxic. Garcia believed metformin to have [[bacteriostatic]], [[Antiviral drug|antiviral]], [[antimalarial]], [[antipyretic]] and [[analgesic]] actions.<ref name=Garcia>Quoted from Chemical Abstracts, v.45, 24828 (1951) {{cite journal | vauthors = Garcia EY |title=Fluamine, a new synthetic analgesic and antiflu drug |journal=J Philippine Med Assoc |volume=26 |issue=7 |pages=287\u201393 |year=1950 |pmid=14779282}}</ref> In a series of articles in 1954, Polish pharmacologist Janusz Supniewski<ref name=\"pmid16766803\">About Janusz Supniewski, see: {{cite journal | vauthors = Wo\u0142kow PP, Korbut R | title = Pharmacology at the Jagiellonian University in Kracow, short review of contribution to global science and cardiovascular research through 400 years of history | journal = Journal of Physiology and Pharmacology | volume = 57 Suppl 1 | issue =  | pages = 119\u201336 | date = April 2006 | pmid = 16766803 | doi =  | url = http://www.jpp.krakow.pl/journal/archive/0406_s1/pdf/119_0406_s1_article.pdf | archive-url = https://web.archive.org/web/20091024211218/http://www.jpp.krakow.pl/journal/archive/0406_s1/pdf/119_0406_s1_article.pdf | df =  | url-status = dead | archive-date = 24 October 2009 | access-date = 22 December 2009 }}</ref> was unable to confirm most of these effects, including lowered blood sugar. Instead he observed antiviral effects in humans.<ref name=\"pmid13269290\">See Chemical Abstracts, v. 52, 22272 (1958) {{cite journal | vauthors = Supniewski J, Chrusciel T | title = [N-dimethyl-di-guanide and its biological properties] | language = Polish | journal = Archivum Immunologiae et Therapiae Experimentalis | volume = 2 | issue =  | pages = 1\u201315 | year = 1954 | pmid = 13269290 | doi =  }}</ref><ref name=supniewski2>Quoted from Chemical Abstracts, v.49, 74699 (1955) {{cite journal | vauthors = Supniewski J, Krupinska J |title=[Effect of biguanide derivatives on experimental cowpox in rabbits] |language=French |journal=Bulletin de l'Academie Polonaise des Sciences, Classe 3: Mathematique, Astronomie, Physique, Chimie, Geologie et Geographie |volume=2(Classe II) |issue= |pages=161\u201365 |year=1954}}</ref>\n\nFrench diabetologist Jean Sterne studied the antihyperglycemic properties of [[galegine]], an [[alkaloid]] isolated from ''[[Galega officinalis]]'', which is related in structure to metformin and had seen brief use as an antidiabetic before the synthalins were developed.<ref name=Bailey>{{cite journal | vauthors = Bailey CJ, Day C |title=Metformin: its botanical background |journal=Practical Diabetes International |volume=21 |issue=3 |pages=115\u201317 |year=2004 |doi=10.1002/pdi.606 |url=http://www3.interscience.wiley.com/cgi-bin/fulltext/108564133/HTMLSTART|archive-url=https://archive.today/20121217224908/http://www3.interscience.wiley.com/cgi-bin/fulltext/108564133/HTMLSTART|url-status=dead|archive-date=2012-12-17}}</ref> Later, working at Laboratoires Aron in Paris, he was prompted by Garcia's report to reinvestigate the blood sugar-lowering activity of metformin and several biguanide analogs. Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name \"Glucophage\" (glucose eater) for the medication and published his results in 1957.<ref name= fifty /><ref name=Bailey />\n\nMetformin became available in the [[British National Formulary]] in 1958. It was sold in the UK by a small Aron subsidiary called Rona.<!--Being a generic drug, it was at a commercial disadvantage; phenformin and buformin were marketed as being more potent and were supported by large pharmaceutical companies with a large sales force. As a result, metformin was used mostly in Scotland and Northern Ireland, while phenformin and buformin achieved worldwide clinical acceptance.--><ref name=\"pmid16402501\">{{cite journal | vauthors = Hadden DR | title = Goat's rue\u2014French lilac\u2014Italian fitch\u2014Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection | journal = The Journal of the Royal College of Physicians of Edinburgh | volume = 35 | issue = 3 | pages = 258\u201360 | date = October 2005 | pmid = 16402501 | doi =  | url = http://www.rcpe.ac.uk/journal/issue/journal_35_3/hadden_goats%20rue.pdf }}</ref>\n\nBroad interest in metformin was not rekindled until the withdrawal of the other biguanides in the 1970s. Metformin was approved in Canada in 1972,<ref>{{cite journal | vauthors = Lucis OJ | title = The status of metformin in Canada | journal = Canadian Medical Association Journal | volume = 128 | issue = 1 | pages = 24\u20136 | date = January 1983 | pmid = 6847752 | pmc = 1874707 }}</ref> but did not receive approval by the U.S. [[Food and Drug Administration]] (FDA) for type 2 diabetes until 1994.<ref name = FDAapproval>{{cite press release |title=FDA Approves New Diabetes Drug |date=30 December 1994 |publisher=U.S. [[Food and Drug Administration]] (FDA) |access-date=2007-01-06 |url=https://www.fda.gov/bbs/topics/ANSWERS/ANS00627.html |archive-url=https://web.archive.org/web/20070929152824/https://www.fda.gov/bbs/topics/ANSWERS/ANS00627.html |archive-date=29 September 2007 |url-status=dead }}</ref> Produced under license by [[Bristol-Myers Squibb]], Glucophage was the first branded formulation of metformin to be marketed in the U.S., beginning on 3 March 1995.<ref>{{cite web | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf | title=Drug Approval Package: Glucophage (metformin) | website=U.S. [[Food and Drug Administration]] (FDA) | archive-url=https://web.archive.org/web/20200205051949/https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf | archive-date=2020-02-05 | url-status=live | access-date=8 January 2007}}</ref> [[generic drug|Generic]] formulations are now available in several countries, and metformin is believed to have become the world's most widely prescribed antidiabetic medication.<ref name=Bailey />\n\n==Society and culture==\n\n=== Environmental ===\nMetformin and its major transformation product guanylurea are present in wastewater treatment plant effluents and regularly detected in surface waters. Guanylurea concentrations above 200 \u03bcg L<sup>\u22121</sup> have been measured in a German river which are amongst the highest reported for pharmaceutical transformation products in aquatic environments.<ref name=\"pmid30350841\">{{cite journal | vauthors = Posselt M, Jaeger A, Schaper JL, Radke M, Benskin JP | title = Determination of polar organic micropollutants in surface and pore water by high-resolution sampling-direct injection-ultra high performance liquid chromatography-tandem mass spectrometry | journal = Environ. Sci.: Process. Impacts | volume = 20 | issue = 12 | pages = 1716\u20131727 | date = December 2018 | pmid = 30350841 | doi = 10.1039/C8EM00390D | doi-access = free }}</ref>\n\n=== Formulations ===\n{{anchor|Formulations}}\n[[File:Metformin 500mg Tablets.jpg|thumb|right|Generic metformin 500-mg tablets, as sold in the United Kingdom]]\n<!-- editors, please note that the trade names noted above redirect to this section i.e. Metformin#Formulations-->\nThe name \"Metformin\" is the [[British Approved Name|BAN]], [[United States Adopted Name|USAN]] and [[International Nonproprietary Name|INN]] for the medication. It is sold under several [[trade name]]s, including Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor, Metfogamma and Glifor.\n\nLiquid metformin is sold under the name Riomet in India. Each 5&nbsp;ml of Riomet is equivalent to the 500-mg tablet form.<ref>{{cite web|url=http://www.rxwiki.com/Metformin|title=Metformin|date=9 July 2012|work=rxwiki|url-status=live|archive-url=https://web.archive.org/web/20130915084453/http://www.rxwiki.com/metformin|archive-date=15 September 2013|df=}}</ref>\n\nMetformin IR (immediate release) is available in 500, 850, and 1000-mg tablets.  All of these are available as generic medications in the U.S.\n\nMetformin SR (slow release) or XR (extended release) was introduced in 2004. It is available in 500, 750, and 1000-mg strengths, mainly to counteract common gastrointestinal side effects, as well as to increase compliance by reducing [[pill burden]]. No difference in effectiveness exists between the two preparations.\n\n==== Combination with other medications ====\nWhen used for type 2 diabetes, metformin is often prescribed in combination with other medications.\n\nSeveral are available as [[fixed-dose combination]]s, to reduce pill burden and simplify administration.<ref name=FDC>{{cite journal | vauthors = Bailey CJ, Day C | title = Fixed-dose single tablet antidiabetic combinations | journal = Diabetes, Obesity & Metabolism | volume = 11 | issue = 6 | pages = 527\u201333 | date = June 2009 | pmid = 19175373 | doi = 10.1111/j.1463-1326.2008.00993.x }}</ref>\n\n==== Thiazolidinediones (glitazones) ====\n\n====Rosiglitazone==== <!-- target of redirect from Avandamet -->\n{{anchor|Rosiglitazone}}\nA combination of metformin and [[rosiglitazone]] was released in 2002 and sold as Avandamet by [[GlaxoSmithKline]].<ref>{{cite press release |title=FDA Approves GlaxoSmithKline's Avandamet (rosiglitazone maleate and metformin HCl), The Latest Advancement in the Treatment of Type 2 Diabetes |publisher=[[GlaxoSmithKline]] |date=12 October 2002 |access-date=2006-12-27 |url=http://www.docguide.com/news/content.nsf/news/8525697700573E1885256C4F0075B2B3 |url-status=live |archive-url=https://web.archive.org/web/20070121050431/http://www.docguide.com/news/content.nsf/news/8525697700573E1885256C4F0075B2B3 |archive-date=21 January 2007 |df= }}</ref>\n\nBy 2009 it had become the most popular metformin combination.<ref>{{cite web |url= http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252010/674969/article.pdf |title= 2009 Top 200 branded drugs by total prescriptions |url-status=dead |archive-url= https://web.archive.org/web/20110714111215/http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252010/674969/article.pdf |archive-date= 2011-07-14 |df=  }}&nbsp;{{small|(96.5&nbsp;KB)}}. ''Drug Topics'' (17 June 2010). Retrieved 2 September 2010.</ref>\n\nIn 2005, the stock of Avandamet was removed from the market, after inspections showed the factory where it was produced was violating [[good manufacturing practice]]s.<ref>{{cite press release |title=Questions and Answers about the Seizure of Paxil CR and Avandamet |publisher=U.S. [[Food and Drug Administration]] |date=4 March 2005 |access-date=2006-12-27 |url=https://www.fda.gov/oc/qanda/PaxilandAvandamet.html |archive-url=https://web.archive.org/web/20071014014507/https://www.fda.gov/oc/qanda/PaxilandAvandamet.html |archive-date=14 October 2007 |url-status=dead }}</ref> The medication pair continued to be prescribed separately and Avandamet was again available by the end of that year. A generic formulation of metformin/rosiglitazone from [[Teva Pharmaceutical Industries|Teva]] received tentative approval from the FDA and reached the market in early 2012.<ref>{{cite press release |url=https://www.reuters.com/article/inPlayBriefing/idUSIN20070927170530TEVA20070927 |title=Teva Pharm announces settlement of generic Avandia, Avandamet, and Avandaryl litigation with GlaxoSmithKline |publisher=Reuters |date=27 September 2007 |access-date=2009-02-17}}</ref>\n\nHowever, following a [[meta-analysis]] in 2007 that linked the medication's use to an increased risk of [[Myocardial infarction|heart attack]],<ref name=\"pmid17517853\">{{cite journal | vauthors = Nissen SE, Wolski K | title = Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes | journal = The New England Journal of Medicine | volume = 356 | issue = 24 | pages = 2457\u201371 | date = June 2007 | pmid = 17517853 | doi = 10.1056/NEJMoa072761 }}</ref>  concerns were raised over the safety of medicines containing rosiglitazone. In September 2010 the [[European Medicines Agency]] (EMA) recommended that the medication be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks.<ref name=\"ema_recommend_suspend\">{{cite web | url = http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=false | publisher = European Medicines Agency | work = News and Events | title = European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim | format =  | access-date =  | url-status=live | archive-url = https://web.archive.org/web/20150924052044/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2010%2F09%2Fnews_detail_001119.jsp&murl=menus%2Fnews_and_events%2Fnews_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=false | archive-date = 2015-09-24 | df =  | date = 2018-09-17 }}</ref><ref name=\"bbc_ema_suspension\">{{cite news | url = https://www.bbc.co.uk/news/health-11397645 | publisher = BBC News | title = Call to 'suspend' diabetes drug | format =  | work =  | access-date =  | date = 2010-09-23 | url-status=live | archive-url = https://web.archive.org/web/20100924044603/http://www.bbc.co.uk/news/health-11397645 | archive-date = 2010-09-24 | df =  }}</ref>\n\nIt was withdrawn from the market in the UK and India in 2010,<ref name=ban>{{cite web|url=http://cdsco.nic.in/html/drugsbanned.html |title=Drugs banned in India |publisher=Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India |access-date=2013-09-17 |url-status=dead |archive-url=https://web.archive.org/web/20150221053621/http://cdsco.nic.in/html/drugsbanned.html |archive-date=2015-02-21 |df= }}</ref> and in New Zealand and South Africa in 2011.<ref name=\"Stuff.co.nz_4669573\">{{cite news |url=http://www.stuff.co.nz/4669573 |title=Diabetes drug withdrawn |date=17 February 2011 |agency=[[NZPA]] |work=[[Stuff.co.nz]] |access-date=5 November 2011}}</ref> From November 2011 until November 2013 the FDA<ref>{{cite news | url = https://www.nytimes.com/2010/02/20/health/policy/20avandia.html | title = Controversial Diabetes Drug Harms Heart, U.S. Concludes | first = Gardiner | last = Harris | name-list-format = vanc | work = [[The New York Times]] | date = 19 February 2010 | url-status=live | archive-url = https://web.archive.org/web/20170319173917/http://www.nytimes.com/2010/02/20/health/policy/20avandia.html | archive-date = 19 March 2017 | df =  }}</ref> did not allow rosiglitazone or metformin/rosiglitazone to be sold without a prescription; moreover, makers were required to notify patients of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies.<ref>{{cite news| url=http://yourlife.usatoday.com/health/medical/heartdisease/story/2011/05/Diabetes-drug-Avandia-to-be-pulled-from-retail-shelves/47316450/1?csp=34news | work=USA Today | title=Most Popular E-mail Newsletter | date=2011-05-24}}</ref>\n\nIn November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label [[randomized control trial]]), which failed to show elevated risk of heart attack or death associated with the medication.<ref name=\"urlGlaxo's Avandia Cleared From Sales Restrictions by FDA \u2013 Bloomberg\">{{cite news | url = https://www.bloomberg.com/news/2013-11-25/glaxo-s-avandia-cleared-from-sales-restrictions-by-fda.html | title = Glaxo's Avandia Cleared From Sales Restrictions by FDA | publisher = Bloomberg | work =  | access-date =  | url-status=live | archive-url = https://web.archive.org/web/20141109083451/http://www.bloomberg.com/news/2013-11-25/glaxo-s-avandia-cleared-from-sales-restrictions-by-fda.html | archive-date = 2014-11-09 | df =  }}</ref><ref>{{cite press release | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm | title = FDA requires removal of certain restrictions on the diabetes drug Avandia | date = 25 November 2013 | website = U.S. [[Food and Drug Administration]] (FDA) | url-status=dead | archive-url = https://web.archive.org/web/20150504051733/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm | archive-date = 4 May 2015 | df =  }}</ref><ref>{{cite web|url=http://blogs.nature.com/news/2013/11/fda-reverses-stance-on-controversial-diabetes-drug.html|title=US agency reverses stance on controversial diabetes drug|publisher=|url-status=live|archive-url=https://web.archive.org/web/20151211005224/http://blogs.nature.com/news/2013/11/fda-reverses-stance-on-controversial-diabetes-drug.html|archive-date=2015-12-11|df=}}</ref>\n\n===== Pioglitazone =====\n{{anchor|Pioglitazone}}\nThe combination of [[Pioglitazone/metformin|metformin and pioglitazone]] (Actoplus Met, Piomet, Politor, Glubrava) is available in the US and in the European Union.<ref>{{cite web | title=Glubrava EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/glubrava | access-date=31 March 2020}}</ref><ref>{{cite web | title=Competact EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/competact | access-date=31 March 2020}}</ref><ref>{{cite web | title=Pioglitazone (marketed as Actos, Actoplus Met, Duetact, and Oseni) Information | website=U.S. [[Food and Drug Administration]] (FDA) | date=11 January 2017 | url=http://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/pioglitazone-marketed-actos-actoplus-met-duetact-and-oseni-information | access-date=31 March 2020}}</ref><ref>{{cite web | title=FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function | website=U.S. [[Food and Drug Administration]] (FDA) | date=3 April 2013 | url=http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain | access-date=31 March 2020}}</ref><ref>{{cite web | title=FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer | website=U.S. [[Food and Drug Administration]] (FDA) | date=4 August 2011 | url=http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone | access-date=31 March 2020}}</ref>\n\n===== DPP-4 inhibitors =====\n{{anchor|DPP-4 inhibitors}}\n[[Dipeptidyl peptidase-4 inhibitor]]s inhibit [[dipeptidyl peptidase-4]] and thus reduce [[glucagon]] and blood glucose levels.\n\nDPP-4 inhibitors combined with metformin include a [[sitagliptin/metformin]] combination and a [[saxagliptin]] combination (Komboglyze), and with [[alogliptin]] as Kazano among others.\n\nMetformin combined with [[linagliptin]] is marketed under the trade name Jentadueto.<ref>{{cite web | title=Jentadueto EPAR | website=European Medicines Agency | url=https://www.ema.europa.eu/en/medicines/human/EPAR/jentadueto | access-date=31 March 2020}}</ref><ref>{{cite web | title=Jentadueto- linagliptin and metformin hydrochloride tablet, film coated | website=DailyMed | date=18 July 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd9b86-0d18-95d4-2bc7-05591bfdd597 | access-date=31 March 2020}}</ref>\n\n===== Sulfonylureas =====\n[[Sulfonylurea]]s act by increasing insulin release from the [[beta cell]]s in the [[pancreas]]. Metformin is available combined with the sulfonylureas [[glipizide]] (Metaglip) and [[glibenclamide]] (US: glyburide) (Glucovance).\n\nGeneric formulations of metformin/glipizide and metformin/glibenclamide are available (the latter is more popular).<ref name=Top200Generics>{{cite web |url= http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf |title= The Use of Medicines in the United States: Review of 2010 |url-status=live |archive-url= https://web.archive.org/web/20110422165905/http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf |archive-date= 2011-04-22 |df=  }}&nbsp;{{small|(1.79&nbsp;MB)}}. IMS Institute for Healthcare Informatics (April 2011). Retrieved 28 April 2011.</ref>\n\n===== Meglitinide =====\n[[Meglitinide]]s are similar to [[sulfonylurea]]s.\n\nA [[repaglinide]]/metformin combination is sold as Prandimet.\n\n===== Triple combination =====\nThe combination of metformin with pioglitazone and glibenclamide<ref>{{cite journal | vauthors = Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C | title = Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy | journal = The Journal of the Association of Physicians of India | volume = 51 | pages = 1061\u20134 | date = November 2003 | pmid = 15260389 }}</ref> is available in India as Triformin.\n\n=== Impurities ===\n{{Anchor|impurities}}\n{{See also|Ranitidine#impurities}}\n\nIn December 2019, the U.S. [[Food and Drug Administration]] (FDA) announced that it learned that some metformin medicines manufactured outside the United States might contain a nitrosamine impurity called [[N-nitrosodimethylamine]] (NDMA), classified as a probable human carcinogen, at low levels.<ref name=\"FDA2019NDMA\">{{cite web | title=Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S. | website=U.S. [[Food and Drug Administration]] (FDA) | date=5 December 2019 | url=http://www.fda.gov/news-events/press-announcements/statement-janet-woodcock-md-director-fdas-center-drug-evaluation-and-research-impurities-found | access-date=4 February 2020}} {{PD-notice}}</ref> Health Canada announced that it was assessing NDMA levels in metformin.<ref name=\"HealthCanada\">{{cite web | title=Recalls and safety alerts | website=Health Canada evaluating NDMA in metformin drugs | date=5 December 2019 | url=https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71831a-eng.php | access-date=4 February 2020}}</ref>\n\nIn February 2020, the FDA found that NDMA levels in tested metformin samples did not exceed the acceptable daily intake.<ref>{{cite web | title=Laboratory Tests - Metformin | website=U.S. [[Food and Drug Administration]] (FDA) | date=3 February 2020 | url=http://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-metformin | access-date=4 February 2020}}</ref><ref>{{cite web | title=FDA Updates and Press Announcements on NDMA in Metformin | website=U.S. Food and Drug Administration | date=4 February 2020 | url=http://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin | access-date=4 February 2020}}</ref>\n\n== Research ==\nMetformin has been studied for its effects on multiple other conditions, including:\n* [[Non-alcoholic fatty liver disease]].<ref name=\"Marchesini\">{{cite journal | vauthors = Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N | title = Metformin in non-alcoholic steatohepatitis | journal = Lancet | volume = 358 | issue = 9285 | pages = 893\u20134 | date = September 2001 | pmid = 11567710 | doi = 10.1016/S0140-6736(01)06042-1 }}</ref><ref>{{cite journal | vauthors = Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H | title = Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review | journal = Journal of Pediatric Gastroenterology and Nutrition | volume = 48 | issue = 5 | pages = 587\u201396 | date = May 2009 | pmid = 19412008 | doi = 10.1097/MPG.0b013e31818e04d1 }}</ref><ref name=\":2\" />\n* [[Premature puberty]].<ref name=\":2\">{{cite journal | vauthors = Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F | title = Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis | journal = Cochrane Database of Systematic Reviews | volume = 24 | issue = 1 | pages = CD005166 | date = January 2007 | pmid = 17253544 | doi = 10.1002/14651858.CD005166.pub2 }} {{Retracted |doi=10.1002/14651858.cd005166.pub3}}</ref><ref>{{cite journal | vauthors = Ib\u00e1\u00f1ez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F | title = Metformin treatment to prevent early puberty in girls with precocious pubarche | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 91 | issue = 8 | pages = 2888\u201391 | date = August 2006 | pmid = 16684823 | doi = 10.1210/jc.2006-0336 | doi-access = free }}</ref>\n* [[anti-cancer|Cancer]].<ref name=\"pmid20442309\">{{cite journal | vauthors = Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F | title = Metformin in cancer therapy: a new perspective for an old antidiabetic drug? | journal = Molecular Cancer Therapeutics | volume = 9 | issue = 5 | pages = 1092\u20139 | date = May 2010 | pmid = 20442309 | doi = 10.1158/1535-7163.MCT-09-1186 | doi-access = free }}</ref><ref name=\"ReferenceA\">{{cite journal | vauthors = Malek M, Aghili R, Emami Z, Khamseh ME | title = Risk of cancer in diabetes: the effect of metformin | journal = ISRN Endocrinology | volume = 2013 | pages = 636927 | date = September 2013 | pmid = 24224094 | pmc = 3800579 | doi = 10.1155/2013/636927 }}</ref>\n* [[Cardiovascular disease]] in people with diabetes.<ref name=\"Cam2017\">{{cite journal | vauthors = Campbell JM, Bellman SM, Stephenson MD, Lisy K | title = Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis | journal = Ageing Research Reviews | volume = 40 | pages = 31\u201344 | date = November 2017 | pmid = 28802803 | doi = 10.1016/j.arr.2017.08.003 }}</ref>\n* While metformin may reduce body weight in persons with fragile X syndrome, it is uncertain whether it improves neurological or psychiatric symptoms.<ref>{{cite journal |vauthors=Gantois I, Popic J, Khoutorsky A, Sonenberg N |display-authors=3 |title=Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders |journal=Annu. Rev. Med. |volume=70 |issue= |pages=167\u2013181 |date=January 2019 |pmid=30365357 |doi=10.1146/annurev-med-081117-041238 |url=}}</ref>\n* Aging (''[[Caenorhabditis elegans|C. elegans]]'' and [[Acheta domesticus|crickets]]).<ref name=\"Pry2015\" /> A 2017 review found that people with diabetes who were taking metformin had lower all-cause mortality. They also had reduced cancer and cardiovascular disease compared with those on other therapies.<ref name=\"Cam2017\" /> {{As of|2016}}, it is being studied to see what effect it may have on aging.<ref>{{cite journal |vauthors=Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA |display-authors=3 |title=Metformin as a Tool to Target Aging |journal=Cell Metabolism |date=June 2016 |volume=23 |issue=6 |pages=1060\u20135 |doi=10.1016/j.cmet.2016.05.011|pmid=27304507 |pmc=5943638 }}</ref>\n\n== References ==\n{{Reflist}}\n\n== Further reading ==\n* {{cite journal |vauthors=Markowicz-Piasecka M, Huttunen KM, Mateusiak L, Mikiciuk-Olasik E, Sikora J |display-authors=3 |title=Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics |journal=Curr. Pharm. Des. |volume=23 |issue=17 |pages=2532\u20132550 |date=2017 |pmid=27908266 |doi=10.2174/1381612822666161201152941 |url=}}\n* {{cite journal |vauthors=McCreight LJ, Bailey CJ, Pearson ER |title=Metformin and the gastrointestinal tract |journal=Diabetologia |volume=59 |issue=3 |pages=426\u201335 |date=March 2016 |pmid=26780750 |pmc=4742508 |doi=10.1007/s00125-015-3844-9 |url=}}\n* {{cite journal |vauthors=Moin T, Schmittdiel JA, Flory JH, Yeh J, Karter AJ, Kruge LE, Schillinger D, Mangione CM, Herman WH, Walker EA |display-authors=3 |title=Review of Metformin Use for Type 2 Diabetes Prevention |journal=Am J Prev Med |volume=55 |issue=4 |pages=565\u2013574 |date=October 2018 |pmid=30126667 |pmc=6613947 |doi=10.1016/j.amepre.2018.04.038 |url=}}\n* {{cite journal |vauthors=Rena G, Hardie DG, Pearson ER |title=The mechanisms of action of metformin |journal=Diabetologia |volume=60 |issue=9 |pages=1577\u20131585 |date=September 2017 |pmid=28776086 |pmc=5552828 |doi=10.1007/s00125-017-4342-z |url=}}\n* {{cite journal |vauthors=Sanchez-Rangel E, Inzucchi SE |title=Metformin: clinical use in type 2 diabetes |journal=Diabetologia |volume=60 |issue=9 |pages=1586\u20131593 |date=September 2017 |pmid=28770321 |doi=10.1007/s00125-017-4336-x |url=|doi-access=free }}\n* {{cite journal |vauthors=Zhou J, Massey S, Story D, Li L |display-authors=3 |title=Metformin: An Old Drug with New Applications |journal=Int J Mol Sci |volume=19 |issue=10 |pages= 2863|date=September 2018 |pmid=30241400 |pmc=6213209 |doi=10.3390/ijms19102863 |url=}}\n* {{cite journal |vauthors=Zhou T, Xu X, Du M, Zhao T, Wang J |display-authors=3 |title=A preclinical overview of metformin for the treatment of type 2 diabetes |journal=Biomed. Pharmacother. |volume=106 |issue= |pages=1227\u20131235 |date=October 2018 |pmid=30119191 |doi=10.1016/j.biopha.2018.07.085 |url=}}\n\n== External links ==\n{{Commons category|Metformin}}\n* {{cite web| url = https://druginfo.nlm.nih.gov/drugportal/name/metformin | publisher = U.S. National Library of Medicine| work = Drug Information Portal| title = Metformin }}\n\n{{Merck Serono|state=autocollapse}}\n{{Oral hypoglycemics and insulin analogs|state=collapsed}}\n{{Portal bar|Pharmacy and pharmacology|Medicine}}\n\n[[Category:Biguanides]]\n[[Category:Drugs with unknown mechanisms of action]]\n[[Category:Guanidines]]\n[[Category:Merck brands]]\n[[Category:World Health Organization essential medicines]]\n[[Category:RTT]]\n", "text_old": "{{short description|Medication}}\n{{Good article}}\n{{Use dmy dates|date=February 2020}}\n{{Infobox drug\n| drug_name         = \n| INN               = \n| type              = <!-- empty -->\n| image = Metformin.svg\n| width = \n| alt               = \n| image2 = Metformin-from-xtal-3D-balls.png\n| width2 = \n| alt2              = \n| caption           = \n\n<!-- Clinical data -->\n| pronounce = {{IPAc-en|m|\u025b|t|\u02c8|f|\u0254\u02d0r|m|\u1d7b|n}}, {{respell|met|FOR|min}}\n| tradename = Fortamet, Glucophage, Glumetza, others\n| Drugs.com = {{drugs.com|monograph|metformin-hydrochloride}}\n| MedlinePlus = a696005\n| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->\n| licence_EU = Yes\n| DailyMedID = Metformin\n| licence_US = Metformin\n| pregnancy_AU = C\n| pregnancy_AU_comment = <ref name=\"Drugs.com pregnancy\">{{cite web | title=Metformin Use During Pregnancy | website=Drugs.com | date=10 September 2019 | url=https://www.drugs.com/pregnancy/metformin.html | access-date=4 February 2020}}</ref>\n| pregnancy_US = N\n| pregnancy_US_comment = <ref name=\"Drugs.com pregnancy\" />\n| pregnancy_category = \n| dependency_liability = \n| addiction_liability = \n| routes_of_administration = [[Oral administration|By mouth]]\n| class             = \n| ATCvet            = \n| ATC_prefix = A10\n| ATC_suffix = BA02\n| ATC_supplemental  = {{ATC|A10|BD23}} {{ATC|A10|BD02}} {{ATC|A10|BD18}} {{ATC|A10|BD11}} {{ATC|A10|BD25}} {{ATC|A10|BD22}} {{ATC|A10|BD14}} {{ATC|A10|BD16}} {{ATC|A10|BD17}} {{ATC|A10|BD05}} {{ATC|A10|BD15}} {{ATC|A10|BD07}} {{ATC|A10|BD10}} {{ATC|A10|BD13}} {{ATC|A10|BD20}} {{ATC|A10|BD08}} {{ATC|A10|BD03}} \n\n<!-- Legal status -->\n| legal_AU = S4\n| legal_AU_comment = \n| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->\n| legal_BR_comment = \n| legal_CA = Rx-only\n| legal_CA_comment = \n| legal_DE = <!-- Anlage I, II, III or Unscheduled-->\n| legal_DE_comment = \n| legal_NZ = <!-- Class A, B, C -->\n| legal_NZ_comment = \n| legal_UK = POM\n| legal_UK_comment = \n| legal_US = Rx-only\n| legal_US_comment = \n| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->\n| legal_UN_comment = \n| legal_status      = <!--For countries not listed above-->\n\n<!-- Pharmacokinetic data -->\n| bioavailability = 50\u201360%<ref name = D95>{{cite journal | vauthors = Dunn CJ, Peters DH | title = Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus | journal = Drugs | volume = 49 | issue = 5 | pages = 721\u201349 | date = May 1995 | pmid = 7601013 | doi = 10.2165/00003495-199549050-00007 }}</ref><ref name=D03>{{cite journal | vauthors = Hundal RS, Inzucchi SE | title = Metformin: new understandings, new uses | journal = Drugs | volume = 63 | issue = 18 | pages = 1879\u201394 | year = 2003 | pmid = 12930161 | doi = 10.2165/00003495-200363180-00001 }}</ref>\n| protein_bound = Minimal<ref name = D95 />\n| metabolism = Not by liver<ref name = D95 />\n| metabolites = \n| onset             = \n| elimination_half-life = 4\u20138.7 hours<ref name = D95 />\n| duration_of_action = \n| excretion = Urine (90%)<ref name = D95 />\n\n<!-- Identifiers -->\n| index_label = \n| index2_label = hydrochloride\n| CAS_number_Ref = {{cascite|correct}}\n| CAS_number = 657-24-9\n| CAS_number2_Ref = {{cascite|correct}}\n| CAS_number2 = 1115-70-4\n| PubChem = 4091\n| IUPHAR_ligand = 4779\n| DrugBank = DB00331\n| DrugBank_Ref      = \n| ChemSpiderID = 3949\n| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}\n| UNII = 9100L32L2N\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII2 = 786Z46389E\n| UNII2_Ref = {{fdacite|correct|FDA}}\n| KEGG = D04966\n| KEGG_Ref = {{keggcite|correct|kegg}}\n| KEGG2 = C07151\n| KEGG2_Ref = {{keggcite|correct|kegg}}\n| ChEBI = 6801\n| ChEBI_Ref = {{ebicite|correct|EBI}}\n| ChEMBL = 1431\n| ChEMBL_Ref = {{ebicite|correct|EBI}}\n| NIAID_ChemDB      = \n| PDB_ligand        = \n| synonyms = ''N'',''N''-dimethylbiguanide<ref>{{cite journal | vauthors = Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, Conti F | title = Disposition of metformin (N,N-dimethylbiguanide) in man | journal = Clinical Pharmacology and Therapeutics | volume = 24 | issue = 6 | pages = 683\u201393 | date = December 1978 | pmid = 710026 | doi = 10.1002/cpt1978246683 }}</ref>\n\n<!-- Chemical and physical data -->\n| IUPAC_name = ''N'',''N''-Dimethylimidodicarbonimidic diamide\n| chemical_formula  = \n| C=4 | H=11 | N=5\n| molecular_weight = 129.164\n| SMILES = CN(C)C(=N)N=C(N)N\n| Jmol              = \n| StdInChI = 1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)\n| StdInChI_comment = \n| StdInChIKey = XZWYZXLIPXDOLR-UHFFFAOYSA-N\n| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}\n| density = 1.3\u00b10.1<ref name=\"chemsrc\">{{Cite web|url=https://www.chemsrc.com/en/cas/657-24-9_889579.html|title=metformin_msds}}</ref>\n| density_notes     = \n| melting_point = \n| melting_high      = \n| melting_notes     = \n| boiling_point = \n| boiling_notes     = \n| solubility = \n| sol_units         = \n| specific_rotation = \n}}\n\n<!-- Definition and medical uses -->\n'''Metformin''', marketed under the trade name '''Glucophage''' among others, is the [[first-line treatment|first-line]] medication for the treatment of [[diabetes mellitus type 2|type 2 diabetes]],<ref name=AHFS2016 /><ref name=Ann2016>{{cite journal | vauthors = Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S | title = Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis | journal = Annals of Internal Medicine | volume = 164 | issue = 11 | pages = 740\u201351 | date = June 2016 | pmid = 27088241 | doi = 10.7326/M15-2650 }}</ref> particularly in people who are [[overweight]].<ref>{{cite book |title=Clinical Obesity |date=2008 |publisher=John Wiley & Sons |location=Oxford |isbn=978-0-470-98708-7 |page=262 |edition=2nd |url=https://books.google.com/books?id=qGVnItPoPCYC&pg=PA262 |url-status=live |archive-url=https://web.archive.org/web/20170908185309/https://books.google.com/books?id=qGVnItPoPCYC&pg=PA262 |archive-date=2017-09-08}}</ref> It is also used in the treatment of [[polycystic ovary syndrome]].<ref name=AHFS2016 /> It is not associated with weight gain.<ref name=Pres2014>{{cite journal | vauthors =  | title = Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects | journal = Prescrire International | volume = 23 | issue = 154 | pages = 269\u201372 | date = November 2014 | pmid = 25954799 }}</ref> It is taken by mouth.<ref name=AHFS2016 />\n\n<!-- Side effects and mechanism -->\nMetformin is generally well tolerated.<ref>{{cite journal | vauthors = Triggle CR, Ding H | title = Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium | journal = Acta Physiologica | volume = 219 | issue = 1 | pages = 138\u2013151 | date = January 2017 | pmid = 26680745 | doi = 10.1111/apha.12644 }}</ref> Common side effects include [[diarrhea]], [[nausea]], and abdominal pain.<ref name=AHFS2016 /> It has a low risk of causing [[hypoglycemia|low blood sugar]].<ref name=AHFS2016 /> [[Lactic acidosis|High blood lactic acid level]] is a concern if the medication is prescribed inappropriately or in overly large doses.<ref name=\"pmid21617112\">{{cite journal | vauthors = Lipska KJ, Bailey CJ, Inzucchi SE | title = Use of metformin in the setting of mild-to-moderate renal insufficiency | journal = Diabetes Care | volume = 34 | issue = 6 | pages = 1431\u20137 | date = June 2011 | pmid = 21617112 | pmc = 3114336 | doi = 10.2337/dc10-2361 }}</ref> There is a risk of lactic acidosis, which can be life-threatening, in people with severe renal insufficiency who take metformin.<ref name=AHFS2016 /> While no clear harm comes from use during [[pregnancy]], [[insulin]] is generally preferred for [[gestational diabetes]].<ref name=AHFS2016 /><ref>{{cite journal | vauthors = Lautatzis ME, Goulis DG, Vrontakis M | title = Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review | journal = Metabolism | volume = 62 | issue = 11 | pages = 1522\u201334 | date = November 2013 | pmid = 23886298 | doi = 10.1016/j.metabol.2013.06.006 }}</ref> Metformin is a [[biguanide]] antihyperglycemic agent.<ref name=AHFS2016>{{cite web|title=Metformin Hydrochloride|url=https://www.drugs.com/monograph/metformin-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|access-date=2 January 2017|url-status=live|archive-url=https://web.archive.org/web/20161224162245/https://www.drugs.com/monograph/metformin-hydrochloride.html|archive-date=24 December 2016|df=}}</ref> It works by decreasing [[Gluconeogenesis|glucose production]] by the [[liver]] and increasing the insulin sensitivity of body tissues.<ref name=AHFS2016/>\n\n<!-- History, society, and culture -->\nMetformin was discovered in 1922.<ref name=Fis2010>{{cite book|last1=Fischer|first1=Janos|title=Analogue-based Drug Discovery II|date=2010|publisher=John Wiley & Sons|isbn=978-3-527-63212-1|pages=49|url=https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA49|url-status=live|archive-url=https://web.archive.org/web/20170908185310/https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA49|archive-date=2017-09-08|df=}}</ref> French physician Jean Sterne began study in humans in the 1950s.<ref name=Fis2010 /> It was introduced as a medication in France in 1957 and the United States in 1995.<ref name=AHFS2016 /><ref>{{cite book|last1=McKee|first1=Mitchell Bebel Stargrove, Jonathan Treasure, Dwight L.|title=Herb, nutrient, and drug interactions : clinical implications and therapeutic strategies|date=2008|publisher=Mosby/Elsevier|location=St. Louis, Mo.|isbn=978-0-323-02964-3|page=217|url=https://books.google.com/books?id=49kLK--eumEC&pg=PA217|url-status=live|archive-url=https://web.archive.org/web/20170908185309/https://books.google.com/books?id=49kLK--eumEC&pg=PA217|archive-date=2017-09-08|df=}}</ref> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]], the safest and most effective medicines needed in a [[health system]].<ref name=\"WHO21st\">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref> Metformin is the most widely used medication for diabetes taken by mouth.<ref name=Fis2010/> It is available as a [[generic medication]].<ref name=AHFS2016 /> The wholesale price in the [[developed world]] was between {{US$}}0.21 and $5.55 per month {{as of|2014|lc=yes}}.<ref>{{cite web|title=Metformin|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=508&searchYear=2014|access-date=11 January 2016|url-status=live|archive-url=https://web.archive.org/web/20170803055731/http://mshpriceguide.org/en/single-drug-information/?DMFId=508&searchYear=2014|archive-date=3 August 2017|df=}}</ref> In the United States, it costs {{US$|5}} to {{US$|25}} per month.<ref name=AHFS2016 /> In 2017, it was the fourth-most commonly prescribed medication in the United States, with more than 78 million prescriptions.<ref>{{cite web |title=The Top 300 of 2020 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=ClinCalc |accessdate=7 April 2020}}</ref><ref>{{cite web | title=Metformin Hydrochloride - Drug Usage Statistics | website=ClinCalc | date=23 December 2019 | url=https://clincalc.com/DrugStats/Drugs/MetforminHydrochloride | access-date=7 April 2020}}</ref>\n{{TOC limit}}\n\n== Medical uses ==\nMetformin is used to lower the blood sugar in those with [[type 2 diabetes]].<ref name=AHFS2016 />  It is also used as a second line agent for [[infertility]] in those with [[polycystic ovary syndrome]].<ref name=AHFS2016 /><ref name=Lord>{{cite journal | vauthors = Lord JM, Flight IH, Norman RJ | title = Metformin in polycystic ovary syndrome: systematic review and meta-analysis | journal = BMJ | volume = 327 | issue = 7421 | pages = 951\u20133 | date = October 2003 | pmid = 14576245 | pmc = 259161 | doi = 10.1136/bmj.327.7421.951 }}</ref>\n\n=== Type 2 diabetes ===\nThe [[American Diabetes Association]] and the [[American College of Physicians]] each recommend metformin as a first-line agent to treat type 2 diabetes.<ref name=\"comparative effectiveness\">{{cite journal | vauthors = Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S | title = Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations | journal = Annals of Internal Medicine | volume = 154 | issue = 9 | pages = 602\u201313 | date = May 2011 | pmid = 21403054 | pmc = 3733115 | doi = 10.7326/0003-4819-154-9-201105030-00336 }}</ref><ref name=\"Inzucchi SE, Bergenstal RM, Buse JB, et al. 1364\u201379\">{{cite journal | vauthors = Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR | title = Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | journal = Diabetes Care | volume = 35 | issue = 6 | pages = 1364\u201379 | date = June 2012 | pmid = 22517736 | pmc = 3357214 | doi = 10.2337/dc12-0413 }}</ref><ref name=ACP2012>{{cite journal | vauthors = Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P | title = Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians | journal = Annals of Internal Medicine | volume = 156 | issue = 3 | pages = 218\u201331 | date = February 2012 | pmid = 22312141 | doi = 10.7326/0003-4819-156-3-201202070-00011 | doi-access = free }}</ref> It is as effective as [[repaglinide]] and more effective than all other oral diabetes mellitus type 2 drugs.<ref>{{cite journal |vauthors=Jia Y, Lao Y, Zhu H, Li N, Leung SW |display-authors=3 |title=Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials |journal=Obes Rev |volume=20 |issue=1 |pages=1\u201312 |date=January 2019 |pmid=30230172 |doi=10.1111/obr.12753 |url=|doi-access=free }}</ref>\n\n==== Efficacy ====\nThe UK Prospective Diabetes Study, a large clinical trial performed in 1980\u201390s, provided evidence that metformin reduced the rate of adverse [[Circulatory system|cardiovascular]] outcomes in overweight patients with type 2 diabetes relative to other antihyperglycemic agents.<ref name = UKPDS>{{cite journal | vauthors =  | title = Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | journal = Lancet | volume = 352 | issue = 9131 | pages = 854\u201365 | date = September 1998 | pmid = 9742977 | doi = 10.1016/S0140-6736(98)07037-8 }}</ref>  However, accumulated evidence from other and more recent trials reduced confidence in the efficacy of metformin for cardiovascular disease prevention.<ref>{{cite journal | vauthors = Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL | title = Cardiovascular outcomes in trials of oral diabetes medications: a systematic review | journal = Archives of Internal Medicine | volume = 168 | issue = 19 | pages = 2070\u201380 | date = October 2008 | pmid = 18955635 | pmc = 2765722 | doi = 10.1001/archinte.168.19.2070 }}</ref><ref name=\"GroopBoussageon2012\">{{cite journal | vauthors = Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C | title = Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials | journal = PLOS Medicine | volume = 9 | issue = 4 | pages = e1001204 | year = 2012 | pmid = 22509138 | pmc = 3323508 | doi = 10.1371/journal.pmed.1001204 }}</ref> Outcomes are improved even in those with some degree of kidney disease, [[heart failure]], or [[chronic liver disease]].<ref>{{cite journal | vauthors = Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, Wang X, Tang S, Nagi A, Kosinski AS, Williams JW | title = Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review | journal = Annals of Internal Medicine | volume = 166 | issue = 3 | pages = 191\u2013200 | date = February 2017 | pmid = 28055049 | pmc = 5293600 | doi = 10.7326/M16-1901 }}</ref>\n\nTreatment guidelines for major professional associations including the [[European Association for the Study of Diabetes]], the European Society for Cardiology, and the [[American Diabetes Association]], now describe evidence for the cardiovascular benefits of metformin as equivocal.<ref name=\"Inzucchi SE, Bergenstal RM, Buse JB, et al. 1364\u201379\" /><ref>{{cite journal | vauthors = Ryd\u00e9n L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL | title = ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD\u2014summary | journal = Diabetes & Vascular Disease Research | volume = 11 | issue = 3 | pages = 133\u201373 | date = May 2014 | pmid = 24800783 | doi = 10.1177/1479164114525548 | doi-access = free }}</ref>\n\nIn 2017, the American College of Physicians's guidelines were updated to recognize metformin as the first-line treatment for type 2 diabetes. These guidelines supersede earlier reviews.  For example, a 2014 review found tentative evidence that people treated with [[sulfonylurea]]s had a higher risk of severe low blood sugar events (RR 5.64), though their risk of nonfatal cardiovascular events was lower than the risk of those treated with metformin (RR 0.67). Not enough data were available at that time to determine the relative risk of death or of death from heart disease.<ref>{{cite journal | vauthors = Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstr\u00f8m LH, Almdal T | title = Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis | journal = CMAJ Open | volume = 2 | issue = 3 | pages = E162\u201375 | date = July 2014 | pmid = 25295236 | pmc = 4185978 | doi = 10.9778/cmajo.20130073 }}</ref>\n\nMetformin has little or no effect on body weight in type 2 diabetes compared with [[placebo]],<ref name=\"Johansen1999\">{{cite journal|vauthors=Johansen K|title=Efficacy of metformin in the treatment of NIDDM. Meta-analysis|journal=Diabetes Care|volume=22|issue=1|date=January 1999|pages=33\u20137|issn=0149-5992|doi=10.2337/diacare.22.1.33|pmid=10333900}}</ref> in contrast to sulfonylureas which are associated with weight gain.<ref name=\"Johansen1999\" /> There is some evidence that metformin is associated with weight loss in obesity in the absence of diabetes.<ref name=\"Golay2007\">{{cite journal | vauthors = Golay A | title = Metformin and body weight | journal = International Journal of Obesity | volume = 32 | issue = 1 | pages = 61\u201372 | date = January 2008 | pmid = 17653063 | doi = 10.1038/sj.ijo.0803695 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Mead E, Atkinson G, Richter B, Metzendorf MI, Baur L, Finer N, Corpeleijn E, O'Malley C, Ells LJ | title = Drug interventions for the treatment of obesity in children and adolescents | journal = The Cochrane Database of Systematic Reviews | volume = 11 | pages = CD012436 | date = November 2016 | pmid = 27899001 | pmc = 6472619 | doi = 10.1002/14651858.CD012436 | hdl = 10149/620651 }}</ref> Metformin has a lower risk of [[hypoglycemia]] than the sulfonylureas,<ref name=\"Umesh\" /><ref name=\"Bolen\" /> although hypoglycemia has uncommonly occurred during intense exercise, calorie deficit, or when used with other agents to lower blood glucose.<ref name=\"isbn0071416137\">{{cite book | last1 = DiPiro | first1 = Joseph T. | last2 = Talbert | first2 = Robert L. | last3 = Yee | first3 = Gary C. | last4 = Matzke | first4 = Gary R. | last5 = Wells | first5 = Barbara G. | last6 = Posey | first6 = L. Michael | name-list-format = vanc |title=Pharmacotherapy: a pathophysiologic approach |publisher=McGraw-Hill |location=New York |year=2005 |isbn=978-0-07-141613-9 }}</ref><ref>[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18054 \"Glucophage package insert\"]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.</ref> Metformin modestly reduces [[low density lipoprotein|LDL]] and [[triglyceride]] levels.<ref name=\"Umesh\" /><ref name=\"Bolen\" />\n\n=== Polycystic ovarian syndrome ===\nIn those with [[polycystic ovarian syndrome]] (PCOS), tentative evidence shows that metformin use increases the rate of live births.<ref name=Mor2017>{{cite journal |vauthors=Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH |display-authors=3 |title=Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility |journal==Cochrane Database Syst Rev |date=November 2017 |volume=11 |pages=CD003053 |doi=10.1002/14651858.CD003053.pub6 |pmid=29183107|pmc=6486196 |quote=Our updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low. }}</ref> This includes in those who have not been able to get pregnant with clomiphene.<ref>{{cite journal | vauthors = Ghazeeri GS, Nassar AH, Younes Z, Awwad JT | title = Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview | journal = Acta Obstetricia et Gynecologica Scandinavica | volume = 91 | issue = 6 | pages = 658\u201378 | date = June 2012 | pmid = 22375613 | doi = 10.1111/j.1600-0412.2012.01385.x }}</ref> Metformin does not appear to change the risk of miscarriage.<ref name=Mor2017/> A number of other benefits have also been found both during pregnancy and in nonpregnant people with PCOS.<ref>{{cite journal | vauthors = Kumar P, Khan K | title = Effects of metformin use in pregnant patients with polycystic ovary syndrome | journal = Journal of Human Reproductive Sciences | volume = 5 | issue = 2 | pages = 166\u20139 | date = May 2012 | pmid = 23162354 | pmc = 3493830 | doi = 10.4103/0974-1208.101012 }}</ref><ref>{{cite journal |vauthors=Tay CT, Joham AE, Hiam DS, Gadalla MA, Pundir J, Thangaratinam S, Teede HJ, Moran LJ |display-authors=3 |title=Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. |journal=Clinical Endocrinology |date=November 2018 |volume=89 |issue=5 |pages=535\u201353 |doi=10.1111/cen.13753 |pmid=29846959 |doi-access=free }}</ref> In women with PCOS undergoing ''in vitro'' fertilization, evidence does not support a benefit with respect to live births.<ref>{{cite journal |vauthors=Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR |display-authors=3 |title=Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome |journal=Cochrane Database Syst Rev |volume= |issue=11 |pages=CD006105 |date=November 2014 |pmid=25406011 |doi=10.1002/14651858.CD006105.pub3 |pmc=6953331 |url=}}</ref> The evidence does not support general use during pregnancy for improving maternal and infant outcomes in obese women.<ref>{{cite journal |vauthors=Dodd JM, Grivell RM, Deussen AR, Hague WM |display-authors=3 |title=Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes |journal=Cochrane Database Syst Rev |volume=7 |issue= |pages=CD010564 |date=July 2018 |pmid=30039871 |pmc=6513233 |doi=10.1002/14651858.CD010564.pub2 |url=}}</ref>\n\nThe United Kingdom's [[National Institute for Health and Clinical Excellence]] recommended in 2004 that women with PCOS and a [[body mass index]] above 25 be given metformin for [[anovulation]] and [[infertility]] when other therapies fail to produce results.<ref name=\"NICEfertility\">{{cite book | author=National Collaborating Centre for Women's and Children's Health | title=Fertility: assessment and treatment for people with fertility problems | location=London | publisher=Royal College of Obstetricians and Gynaecologists | year=2004 | isbn=978-1-900364-97-3 | pages=58\u201359 | url=http://www.nice.org.uk/nicemedia/pdf/cg011fullguideline.pdf | url-status=live | archive-url=https://web.archive.org/web/20090711000422/http://www.nice.org.uk/nicemedia/pdf/CG011fullguideline.pdf | archive-date=2009-07-11 | df= }}</ref> UK and international [[clinical practice guideline]]s do not recommend metformin as a first-line treatment<ref>{{cite web | vauthors = Balen A |title=Metformin therapy for the management of infertility in women with polycystic ovary syndrome |work=Scientific Advisory Committee Opinion Paper 13 |publisher=Royal College of Obstetricians and Gynaecologists |date=December 2008 |url=http://www.rcog.org.uk/files/rcog-corp/uploaded-files/SAC13metformin-minorrevision.pdf |access-date=2009-12-13 |url-status=dead |archive-url=https://www.webcitation.org/5m73m3kuM?url=http://www.rcog.org.uk/files/rcog-corp/uploaded-files/SAC13metformin-minorrevision.pdf |archive-date=2009-12-18 |df= }}</ref> or do not recommend it at all, except for women with [[glucose intolerance]].<ref name=\"pmid18308833\">{{cite journal | author = The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group | title = Consensus on infertility treatment related to polycystic ovary syndrome | journal = Human Reproduction | volume = 23 | issue = 3 | pages = 462\u201377 | date = March 2008 | pmid = 18308833 | doi = 10.1093/humrep/dem426 | doi-access = free }}</ref> The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from medical treatment. Metformin treatment decreases the risk of developing type 2 diabetes mellitus in women with PCOS who exhibited impaired glucose tolerance (IGT) at baseline.<ref name=\"pmid20840272\"/><ref name=\"pmid19841045\">{{cite journal | vauthors = Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN | title = Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome | journal = European Journal of Endocrinology | volume = 162 | issue = 2 | pages = 193\u2013212 | date = February 2010 | pmid = 19841045 | doi = 10.1530/EJE-09-0733 | doi-access = free }}</ref>\n\n=== Diabetes mellitus and pregnancy ===\nA review of metformin use during pregnancy compared to insulin alone found good short-term safety for both the mother and baby, but unclear long-term safety.<ref>{{cite journal | vauthors = Butalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L | title = Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis | journal = Diabetic Medicine | volume = 34 | issue = 1 | pages = 27\u201336 | date = January 2017 | pmid = 27150509 | doi = 10.1111/dme.13150 }}</ref> Several [[observational study|observational studies]] and randomized, controlled trials found metformin to be as effective and safe as insulin for the management of gestational diabetes.<ref name=Nicholson>{{cite journal | vauthors = Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E | title = Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review | journal = Obstetrics and Gynecology | volume = 113 | issue = 1 | pages = 193\u2013205 | date = January 2009 | pmid = 19104375 | doi = 10.1097/AOG.0b013e318190a459 }}</ref><ref>{{cite journal | vauthors = Kitwitee P, Limwattananon S, Limwattananon C, Waleekachonlert O, Ratanachotpanich T, Phimphilai M, Nguyen TV, Pongchaiyakul C | title = Metformin for the treatment of gestational diabetes: An updated meta-analysis | journal = Diabetes Research and Clinical Practice | volume = 109 | issue = 3 | pages = 521\u201332 | date = September 2015 | pmid = 26117686 | doi = 10.1016/j.diabres.2015.05.017 }}</ref> Nonetheless, several concerns have been raised and evidence on the long-term safety of metformin for both mother and child is lacking.<ref name=\"Balsells2015\">{{cite journal | vauthors = Balsells M, Garc\u00eda-Patterson A, Sol\u00e0 I, Roqu\u00e9 M, Gich I, Corcoy R | title = Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis | journal = BMJ | volume = 350 | pages = h102 | date = January 2015 | pmid = 25609400 | pmc = 4301599 | doi = 10.1136/bmj.h102 | type = Systematic Review & Meta-Analysis }}</ref> Compared with insulin, women with gestational diabetes treated with metformin gain less weight and are less likely to develop pre\u2010eclampsia during pregnancy.<ref name=\"Balsells2015\" /><ref>{{cite journal |vauthors=Alqudah A, McKinley MC, McNally R, Graham U, Watson CJ, Lyons TJ, McClements L |display-authors=3 |title=Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis |journal=Diabet. Med. |volume=35 |issue=2 |pages=160\u2013172 |date=February 2018 |pmid=29044702 |doi=10.1111/dme.13523 |url=https://pure.qub.ac.uk/portal/en/publications/the-risk-of-preeclampsia-in-women-taking-metformin-systematic-review-and-metaanalysis(8020376c-6e9c-4795-af4b-15441b5773bf).html}}</ref> Babies born to women treated with metformin have less [[visceral fat]], and this may make them less prone to insulin resistance in later life.<ref name=\"SivalingamMyers2014\">{{cite journal | vauthors = Sivalingam VN, Myers J, Nicholas S, Balen AH, Crosbie EJ | title = Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications | journal = Human Reproduction Update | volume = 20 | issue = 6 | pages = 853\u201368 | year = 2014 | pmid = 25013215 | doi = 10.1093/humupd/dmu037 | doi-access = free }}</ref> The use of metformin for gestational diabetes resulted in smaller babies compared to treatment with insulin. However, despite initially lower birth weight, children exposed to metformin during pregnancy had accelerated growth after birth, and were heavier by mid-childhood than those exposed to insulin during pregnancy. This pattern of initial low birth weight followed by catch-up growth that surpasses comparative children has been associated with long-term cardio-metabolic disease.<ref>{{cite journal |vauthors=Tarry-Adkins JL, Aiken CE, Ozanne SE |title=Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis |journal=PLOS Med. |volume=16 |issue=8 |pages=e1002848 |date=August 2019 |pmid=31386659 |pmc=6684046 |doi=10.1371/journal.pmed.1002848 |url=}}</ref>\n\n=== Weight change===\nMetformin is typically associated with weight loss.<ref>{{cite journal |vauthors=Yerevanian A, Soukas AA |title=Metformin: Mechanisms in Human Obesity and Weight Loss |journal=Current Obesity Reports |date=June 2019 |volume=8 |issue=2 |pages=156\u201364 |doi=10.1007/s13679-019-00335-3 |pmid=30874963|pmc=6520185 }}</ref> Metformin appears to be safe and effective in counteracting  the weight gain caused by the [[antipsychotic]] medications [[olanzapine]] and [[clozapine]].<ref name=Choi2015>{{cite journal | vauthors = Choi YJ | title = Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis | journal = TheScientificWorldJournal | volume = 2015 | pages = 1\u201310 | year = 2015 | pmid = 25664341 | pmc = 4310265 | doi = 10.1155/2015/970730 }}</ref><ref name=PraharajJana2011>{{cite journal | vauthors = Praharaj SK, Jana AK, Goyal N, Sinha VK | title = Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis | journal = British Journal of Clinical Pharmacology | volume = 71 | issue = 3 | pages = 377\u201382 | date = March 2011 | pmid = 21284696 | pmc = 3045546 | doi = 10.1111/j.1365-2125.2010.03783.x }}</ref> Although modest reversal of clozapine-associated weight gain is found with metformin, primary prevention of weight gain is more valuable.<ref name=HolscherSiskind2016>{{cite journal | vauthors = Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S | title = Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis | journal = PLOS One | volume = 11 | issue = 6 | pages = e0156208 | year = 2016 | pmid = 27304831 | pmc = 4909277 | doi = 10.1371/journal.pone.0156208 | bibcode = 2016PLoSO..1156208S }}</ref>\n\n===Use with insulin===\nMetformin may reduce the insulin requirement in [[Diabetes mellitus type 1|type 1 diabetes]], albeit with an increased risk of hypoglycemia.<ref name=\":0\">{{cite journal | vauthors = Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR | title = The use of metformin in type 1 diabetes: a systematic review of efficacy | journal = Diabetologia | volume = 53 | issue = 5 | pages = 809\u201320 | date = May 2010 | pmid = 20057994 | doi = 10.1007/s00125-009-1636-9 | doi-access = free }}</ref>\n\n== Contraindications ==\nThe FDA revised its [[package insert|prescribing information]] on metformin in 2016.<ref name=\"FDA Safety\" />{{update inline|date=February 2020}}\n\nMetformin is [[contraindication|contraindicated]] in people with:\n* severe renal impairment (estimated [[Renal function|glomerular filtration rate]] (eGFR) below 30 ml/min/1.73 m2)\n* known hypersensitivity to metformin\n* acute or chronic [[metabolic acidosis]], including [[diabetic ketoacidosis]], with or without [[coma]]\n\nWarnings are also given regarding the use of metformin in less severe renal impairment, people aged 65 years old or greater,  [[Hypoxia (medical)|hypoxic]] states (e.g., [[Heart failure|acute congestive heart failure)]], excessive alcohol intake, [[Liver disease|hepatic impairment]], concomitant use of certain drugs (e.g. [[carbonic anhydrase inhibitor]]s such as [[topiramate]]), surgery, and other procedures, or in people having a radiological study with administration of an [[iodine|iodinated]] [[radiocontrast|contrast]] agent.\n\nMetformin is recommended to be temporarily discontinued before any procedure involving use of iodinated contrast agents, (such as a contrast-enhanced [[computed tomography|CT scan]] or [[angiogram]]) due to the increased risk of lactic acidosis resulting from impaired kidney function;<ref name=\"RCR\">Weir J (19 March 1999). [https://web.archive.org/web/20040104141219/http://www.rcr.ac.uk/pubtop.asp?PublicationID=70 Guidelines with Regard to Metformin-Induced Lactic Acidosis and X-ray Contrast Medium Agents]. [[Royal College of Radiologists]]. Retrieved 26 October 2007 through the [[Internet Archive]].</ref><ref name=\"ESUR\">{{cite journal | vauthors = Thomsen HS, Morcos SK | title = Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines | journal = The British Journal of Radiology | volume = 76 | issue = 908 | pages = 513\u20138 | date = August 2003 | pmid = 12893691 | doi = 10.1259/bjr/26964464 }}</ref> metformin can be resumed after two days after contrast administration, if renal function is adequate and stable.\n\n== Adverse effects ==\nThe most common [[adverse drug reaction|adverse effect]] of metformin is gastrointestinal irritation, including [[diarrhea]], cramps, nausea, vomiting, and increased [[flatulence]]; metformin is more commonly associated with gastrointestinal side effects than most other antidiabetic medications.<ref name=Bolen>{{cite journal | vauthors = Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL | title = Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus | journal = Annals of Internal Medicine | volume = 147 | issue = 6 | pages = 386\u201399 | date = September 2007 | pmid = 17638715 | doi = 10.7326/0003-4819-147-6-200709180-00178 | doi-access = free }}</ref> The most serious potential side effect of metformin use is [[lactic acidosis]]; this complication is very rare, and the vast majority of these cases seem to be related to comorbid conditions, such as impaired liver or kidney function, rather than to the metformin itself.<ref>{{cite journal | vauthors = Khurana R, Malik IS | title = Metformin: safety in cardiac patients | journal = Heart | volume = 96 | issue = 2 | pages = 99\u2013102 | date = January 2010 | pmid = 19564648 | doi = 10.1136/hrt.2009.173773 }}</ref>\n\n=== Gastrointestinal ===\nGastrointestinal upset can cause severe discomfort; it is most common when metformin is first administered, or when the dose is increased. The discomfort can often be avoided by beginning at a low dose (1.0 to 1.7&nbsp;grams per day) and increasing the dose gradually, but even with low doses, 5% of people may be unable to tolerate metformin.<ref name=\":1\">{{cite journal | vauthors = Fujita Y, Inagaki N | title = Metformin: New Preparations and Nonglycemic Benefits | journal = Current Diabetes Reports | volume = 17 | issue = 1 | pages = 5 | date = January 2017 | pmid = 28116648 | doi = 10.1007/s11892-017-0829-8 }}</ref> Use of slow- or extended-release preparations may improve tolerability.<ref name=\":1\" />\n\nLong-term use of metformin has been associated with increased [[homocysteine]] levels<ref name=Wulffele>{{cite journal | vauthors = Wulffel\u00e9 MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD | title = Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial | journal = Journal of Internal Medicine | volume = 254 | issue = 5 | pages = 455\u201363 | date = November 2003 | pmid = 14535967 | doi = 10.1046/j.1365-2796.2003.01213.x | url = https://semanticscholar.org/paper/214429d3c5eadc51e1ee7d70f080b4c5a1f1087d }}</ref> and [[malabsorption]] of [[cyanocobalamin|vitamin B<sub>12</sub>]].<ref name = Andres>{{cite journal | vauthors = Andr\u00e8s E, Noel E, Goichot B | title = Metformin-associated vitamin B12 deficiency | journal = Archives of Internal Medicine | volume = 162 | issue = 19 | pages = 2251\u20132 | date = October 2002 | pmid = 12390080 | doi = 10.1001/archinte.162.19.2251-a }}</ref><ref name = Gilligan>{{cite journal | vauthors = Gilligan MA | title = Metformin and vitamin B12 deficiency | journal = Archives of Internal Medicine | volume = 162 | issue = 4 | pages = 484\u20135 | date = February 2002 | pmid = 11863489 | doi = 10.1001/archinte.162.4.484 }}</ref> Higher doses and prolonged use are associated with increased incidence of [[Vitamin B12 deficiency|vitamin B<sub>12</sub> deficiency]],<ref>{{cite journal | vauthors = de Jager J, Kooy A, Lehert P, Wulffel\u00e9 MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD | title = Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial | journal = BMJ | volume = 340 | pages = c2181 | date = May 2010 | pmid = 20488910 | pmc = 2874129 | doi = 10.1136/bmj.c2181 }}</ref> and some researchers recommend screening or prevention strategies.<ref>{{cite journal | vauthors = Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM | title = Risk factors of vitamin B(12) deficiency in patients receiving metformin | journal = Archives of Internal Medicine | volume = 166 | issue = 18 | pages = 1975\u20139 | date = October 2006 | pmid = 17030830 | doi = 10.1001/archinte.166.18.1975 | doi-access = free }}</ref>\n\n=== Lactic acidosis ===\n[[Lactic acidosis]] almost never occurs with metformin exposure during routine medical care.<ref>{{cite journal |vauthors=Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B |display-authors=3 |title=Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes |journal=Diabetologia |volume=52 |issue=1 |pages=17\u201330 |date=January 2009 |pmid=18941734 |doi=10.1007/s00125-008-1157-y |url=|doi-access=free }}</ref> Rates of metformin-associated lactic acidosis is about nine per 100,000 person-years, which is similar to the background rate of lactic acidosis in the general population.<ref name=\"Stang\">{{cite journal | vauthors = Stang M, Wysowski DK, Butler-Jones D | title = Incidence of lactic acidosis in metformin users | journal = Diabetes Care | volume = 22 | issue = 6 | pages = 925\u20137 | date = June 1999 | pmid = 10372243 | doi = 10.2337/diacare.22.6.925 }}</ref> A systematic review concluded no data exists to definitively link metformin to lactic acidosis.<ref name=Salpeter>{{cite journal | vauthors = Salpeter SR, Greyber E, Pasternak GA, Salpeter EE | title = Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis | journal = Archives of Internal Medicine | volume = 163 | issue = 21 | pages = 2594\u2013602 | date = November 2003 | pmid = 14638559 | doi = 10.1001/archinte.163.21.2594 | doi-access = free }}</ref>\n\nMetformin is generally safe in people with mild to moderate chronic kidney disease, with proportional reduction of metformin dose according to severity of estimated glomerular filtration rate and with periodic assessment of kidney function, (e.g., periodic plasma creatinine measurement).<ref>{{cite journal |vauthors=Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK |display-authors=3 |title=Metformin in patients with type 2 diabetes and kidney disease: a systematic review |journal=JAMA |volume=312 |issue=24 |pages=2668\u201375 |date=2014 |pmid=25536258 |pmc=4427053 |doi=10.1001/jama.2014.15298 |url=}}</ref> The [[FDA]] recommends avoiding the use of metformin in more severe chronic kidney disease, below the [[estimated glomerular filtration rate]] (eGFR) cutoff of 30 mL/minute/1.73 m<sup>2</sup>.<ref name=\"FDA Safety\">{{cite web |title=FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function |url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain |website=U.S. [[Food and Drug Administration]] (FDA) |accessdate=21 December 2018 |date=14 November 2017 }}</ref> Lactate uptake by the liver is diminished with metformin use because lactate is a [[Substrate (biochemistry)|substrate]] for hepatic [[gluconeogenesis]], a process that metformin inhibits. In healthy individuals, this slight excess is cleared by other mechanisms (including uptake by unimpaired kidneys), and no significant elevation in blood levels of lactate occurs.<ref name=Umesh>{{cite book |vauthors=Maharani U |veditors=Papadakis MA, McPhee SJ |chapter=Chapter 27: Diabetes Mellitus & Hypoglycemia |title=Current Medical Diagnosis and Treatment 2010 |edition=49th |publisher=McGraw-Hill Medical |location= |year=2009 |pages=[https://archive.org/details/isbn_9780071624442/page/1092 1092\u201393] |isbn=978-0-07-162444-2 |url-access=registration |url=https://archive.org/details/isbn_9780071624442/page/1092 }}</ref> Given severely-impaired kidney function, clearance of metformin and lactate is reduced, increasing levels of both, and possibly causing lactic acid buildup. Because metformin decreases liver uptake of lactate, any condition that may precipitate lactic acidosis is a contraindication. Common causes include [[alcoholism]] (due to depletion of [[nicotinamide adenine dinucleotide|NAD+]] stores), heart failure and respiratory disease (due to inadequate tissue oxygenation); the most common cause is kidney disease.<ref name=Golan>{{cite book | vauthors = Shu AD, Myers MG, Shoelson SE | veditors = Golan ED, Tashjian AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS | chapter=Chapter 29: Pharmacology of the Endocrine Pancreas |title=Principles of pharmacology: the pathophysiologic basis of drug therapy |publisher=Lippincott, Williams & Wilkins |location=Philadelphia |year=2005 |pages=540\u201341 |isbn=978-0-7817-4678-6}}</ref>\n\nMetformin has been suggested as increasing production of lactate in the large intestine, which could potentially contribute to lactic acidosis in those with risk factors.<ref name=Kirpichnikov>{{cite journal | vauthors = Kirpichnikov D, McFarlane SI, Sowers JR | title = Metformin: an update | journal = Annals of Internal Medicine | volume = 137 | issue = 1 | pages = 25\u201333 | date = July 2002 | pmid = 12093242 | doi = 10.7326/0003-4819-137-1-200207020-00009 }}</ref> However, the clinical significance of this is unknown, and the risk of metformin-associated lactic acidosis is most commonly attributed to decreased hepatic uptake rather than increased intestinal production.<ref name=Umesh /><ref name=Golan /><ref>{{cite book | vauthors = Davis SN | veditors = Brunton L, Lazo J, Parker K |title=Goodman & Gilman's The Pharmacological Basis of Therapeutics |edition=11th |year=2006 |publisher=[[McGraw-Hill]] |location=New York |isbn=978-0-07-142280-2 |pages= |chapter=Chapter 60: Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the Endocrine Pancreas| title-link = Goodman & Gilman's The Pharmacological Basis of Therapeutics }}</ref>\n\nThe risk of metformin-associated lactic acidosis is also increased by massive overdose of metformin, although even quite large doses are often not fatal.<ref name=\"Teale\">{{cite journal | vauthors = Teale KF, Devine A, Stewart H, Harper NJ | title = The management of metformin overdose | journal = Anaesthesia | volume = 53 | issue = 7 | pages = 698\u2013701 | date = July 1998 | pmid = 9771180 | doi = 10.1046/j.1365-2044.1998.436-az0549.x }}</ref>\n\n=== Overdose ===\nThe most common symptoms following overdose include vomiting, [[diarrhea]], abdominal pain, [[tachycardia]], drowsiness, and, rarely, [[hypoglycemia]] or [[hyperglycemia]].<ref name=\"Forrester\">{{cite journal | vauthors = Forrester MB | title = Adult metformin ingestions reported to Texas poison control centers, 2000-2006 | journal = Human & Experimental Toxicology | volume = 27 | issue = 7 | pages = 575\u201383 | date = July 2008 | pmid = 18829734 | doi = 10.1177/0960327108090589 | citeseerx = 10.1.1.1031.9486 }}</ref><ref name=\"Suchard\">{{cite journal | vauthors = Suchard JR, Grotsky TA | title = Fatal metformin overdose presenting with progressive hyperglycemia | journal = The Western Journal of Emergency Medicine | volume = 9 | issue = 3 | pages = 160\u20134 | date = August 2008 | pmid = 19561734 | pmc = 2672258 }}</ref>  Treatment of metformin overdose is generally supportive, as no specific antidote is known. Extracorporeal treatments are recommended in severe overdoses.<ref name=Cal2015>{{cite journal | vauthors = Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, Hoffman RS, Nolin TD, Ghannoum M | title = Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup | journal = Critical Care Medicine | volume = 43 | issue = 8 | pages = 1716\u201330 | date = August 2015 | pmid = 25860205 | doi = 10.1097/CCM.0000000000001002 }}</ref> Due to metformin's low [[molecular weight]] and lack of [[plasma protein binding]], these techniques have the benefit of removing metformin from [[blood plasma]], preventing further lactate overproduction.<ref name=Cal2015 />\n\nMetformin may be quantified in blood, plasma, or serum to monitor therapy, confirm a diagnosis of poisoning, or assist in a forensic death investigation. Blood or plasma metformin concentrations are usually in a range of 1\u20134&nbsp;mg/l in persons receiving therapeutic doses, 40\u2013120&nbsp;mg/l in victims of acute overdosage, and 80\u2013200&nbsp;mg/l in fatalities. Chromatographic techniques are commonly employed.<ref>{{cite journal | vauthors = Liu A, Coleman SP | title = Determination of metformin in human plasma using hydrophilic interaction liquid chromatography-tandem mass spectrometry | journal = Journal of Chromatography B | volume = 877 | issue = 29 | pages = 3695\u2013700 | date = November 2009 | pmid = 19783231 | doi = 10.1016/j.jchromb.2009.09.020 }}</ref><ref>R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 939\u2013940.</ref>\n\n=== Interactions ===\nThe [[H2 antagonist|H<sub>2</sub>-receptor antagonist]] [[cimetidine]] causes an increase in the plasma concentration of metformin by reducing [[clearance (medicine)|clearance]] of metformin by the kidneys;<ref>{{cite journal | vauthors = Somogyi A, Stockley C, Keal J, Rolan P, Bochner F | title = Reduction of metformin renal tubular secretion by cimetidine in man | journal = British Journal of Clinical Pharmacology | volume = 23 | issue = 5 | pages = 545\u201351 | date = May 1987 | pmid = 3593625 | pmc = 1386190 | doi = 10.1111/j.1365-2125.1987.tb03090.x }}</ref> both metformin and cimetidine are cleared from the body by [[Renal physiology#Secretion|tubular secretion]], and both, particularly the [[cation]]ic (positively [[electric charge|charged]]) form of cimetidine, may compete for the same transport mechanism.<ref name=PI /> A small [[blind experiment|double-blind]], randomized study found the [[antibiotic]] [[cephalexin]] to also increase metformin concentrations by a similar mechanism;<ref>{{cite journal | vauthors = Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y | title = Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers | journal = Drug Metabolism and Drug Interactions | volume = 19 | issue = 1 | pages = 41\u20138 | year = 2002 | pmid = 12222753 | doi = 10.1515/dmdi.2002.19.1.41 }}</ref> theoretically, other cationic medications may produce the same effect.<ref name=PI />\n\nMetformin also interacts with [[anticholinergic]] medications, due to their effect on gastric motility. Anticholinergic drugs reduce gastric motility, prolonging the time drugs spend in the [[gastrointestinal tract]]. This impairment may lead to more metformin being absorbed than without the presence of an anticholinergic drug, thereby increasing the concentration of metformin in the plasma and increasing the risk for adverse effects.<ref name=\"May DDI Review\">{{cite journal | vauthors = May M, Schindler C | title = Clinically and pharmacologically relevant interactions of antidiabetic drugs | journal = Therapeutic Advances in Endocrinology and Metabolism | volume = 7 | issue = 2 | pages = 69\u201383 | date = April 2016 | pmid = 27092232 | pmc = 4821002 | doi = 10.1177/2042018816638050 }}</ref>\n\n== Pharmacology ==\n\n=== Mechanism of action ===\nThe molecular mechanism of metformin is not completely understood. Multiple potential mechanisms of action have been proposed: inhibition of the mitochondrial respiratory chain (complex I), activation of [[AMP-activated protein kinase]] (AMPK), inhibition of glucagon-induced elevation of [[cyclic adenosine monophosphate]] (cAMP) with reduced activation of [[protein kinase A]] (PKA), inhibition of mitochondrial [[Glycerol-3-phosphate dehydrogenase|glycerophosphate dehydrogenase]], and an effect on [[gut flora|gut microbiota]].<ref name=\"Rena_2013\">{{cite journal | vauthors = Rena G, Pearson ER, Sakamoto K | title = Molecular mechanism of action of metformin: old or new insights? | journal = Diabetologia | volume = 56 | issue = 9 | pages = 1898\u2013906 | date = September 2013 | pmid = 23835523 | pmc = 3737434 | doi = 10.1007/s00125-013-2991-0 }}</ref><ref name =\"Burcelin\">{{cite journal | vauthors = Burcelin R | title = The antidiabetic gutsy role of metformin uncovered? | journal = Gut | volume = 63 | issue = 5 | pages = 706\u20137 | date = May 2014 | pmid = 23840042 | doi = 10.1136/gutjnl-2013-305370 }}</ref><ref>{{cite journal | vauthors = Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI | title = Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase | journal = Nature | volume = 510 | issue = 7506 | pages = 542\u20136 | date = June 2014 | pmid = 24847880 | pmc = 4074244 | doi = 10.1038/nature13270 | bibcode = 2014Natur.510..542M }}</ref> Ultimately, it decreases [[gluconeogenesis]] (glucose production) in the liver.<ref name=Kirpichnikov /><ref name=\"pmid26680745\">{{cite journal | vauthors=Triggle CR, Ding H | title=Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium | journal= [[Acta Physiologica]] | volume=219 | issue=1 | pages=138\u2013151 | year=2017 | doi= 10.1111/apha.12644 | pmid = 26680745}}</ref>  It also has an insulin-sensitizing effect with multiple actions on tissues including the liver, skeletal muscle, endothelium, adipose tissue, and the ovary.<ref name=\"pmid20840272\">{{cite journal | vauthors = Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C | title = Metformin in polycystic ovary syndrome | journal = Annals of the New York Academy of Sciences | volume = 1205 | issue = 1 | pages = 192\u20138 | date = September 2010 | pmid = 20840272 | doi = 10.1111/j.1749-6632.2010.05679.x | bibcode = 2010NYASA1205..192D }}</ref><ref name=\"pmid14576245\">{{cite journal | vauthors = Lord JM, Flight IH, Norman RJ | title = Metformin in polycystic ovary syndrome: systematic review and meta-analysis | journal = BMJ | volume = 327 | issue = 7421 | pages = 951\u20133 | date = October 2003 | pmid = 14576245 | doi = 10.1136/bmj.327.7421.951 | pmc = 259161 }}</ref> The average patient with type 2 diabetes has three times the normal rate of gluconeogenesis; metformin treatment reduces this by over one-third.<ref name=Hundal>{{cite journal | vauthors = Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI | title = Mechanism by which metformin reduces glucose production in type 2 diabetes | journal = Diabetes | volume = 49 | issue = 12 | pages = 2063\u20139 | date = December 2000 | pmid = 11118008 | pmc = 2995498 | doi = 10.2337/diabetes.49.12.2063 }}</ref>\n\nActivation of [[AMPK]] was required for metformin's inhibitory effect on liver glucose production.<ref name=\"Zhou\">{{cite journal | vauthors = Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE | title = Role of AMP-activated protein kinase in mechanism of metformin action | journal = The Journal of Clinical Investigation | volume = 108 | issue = 8 | pages = 1167\u201374 | date = October 2001 | pmid = 11602624 | pmc = 209533 | doi = 10.1172/JCI13505 }}</ref> AMPK is an enzyme that plays an important role in insulin signalling, whole body energy balance and the metabolism of glucose and [[lipid|fats]].<ref>{{cite journal | vauthors = Towler MC, Hardie DG | title = AMP-activated protein kinase in metabolic control and insulin signaling | journal = Circulation Research | volume = 100 | issue = 3 | pages = 328\u201341 | date = February 2007 | pmid = 17307971 | doi = 10.1161/01.RES.0000256090.42690.05 | doi-access = free }}</ref> AMPK Activation was required for an increase in the expression of [[small heterodimer partner]], which in turn inhibited the [[gene expression|expression]] of the hepatic gluconeogenic genes [[phosphoenolpyruvate carboxykinase]] and [[glucose 6-phosphatase]].<ref>{{cite journal | vauthors = Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK, Lee CH, Choi HS | title = Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP | journal = Diabetes | volume = 57 | issue = 2 | pages = 306\u201314 | date = February 2008 | pmid = 17909097 | doi = 10.2337/db07-0381 | doi-access = free }}</ref> Metformin is frequently used in research along with [[AICA ribonucleotide]] as an AMPK agonist.  The mechanism by which biguanides increase the activity of AMPK remains uncertain; however, metformin increases the concentration of [[cytosol]]ic [[adenosine monophosphate]] (AMP) (as opposed to a change in total AMP or total AMP/[[adenosine triphosphate]]).<ref>{{cite journal | vauthors = Zhang L, He H, Balschi JA | title = Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration | journal = American Journal of Physiology. Heart and Circulatory Physiology | volume = 293 | issue = 1 | pages = H457\u201366 | date = July 2007 | pmid = 17369473 | doi = 10.1152/ajpheart.00002.2007 }}</ref> Increased cellular AMP has been proposed to explain the inhibition of glucagon-induced increase in cAMP and activation of PKA.<ref name=\"Rena_2013\" /> Metformin and other biguanides may antagonize the action of [[glucagon]], thus reducing fasting glucose levels.<ref name=\"Miller2013\">{{cite journal | vauthors = Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ | title = Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP | journal = Nature | volume = 494 | issue = 7436 | pages = 256\u201360 | date = February 2013 | pmid = 23292513 | pmc = 3573218 | doi = 10.1038/nature11808 | bibcode = 2013Natur.494..256M }}</ref> Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice and this may contribute to its mode of action possibly through an effect on [[glucagon-like peptide-1]] secretion.<ref name=\"Burcelin\" />\n\nIn addition to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances peripheral [[glucose uptake]] (by inducing the phosphorylation of [[GLUT4]] enhancer factor), decreases insulin-induced suppression of [[fatty acid metabolism|fatty acid oxidation]],<ref name=Collier>{{cite journal | vauthors = Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ | title = Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle | journal = American Journal of Physiology. Endocrinology and Metabolism | volume = 291 | issue = 1 | pages = E182\u20139 | date = July 2006 | pmid = 16478780 | doi = 10.1152/ajpendo.00272.2005 }}</ref> and decreases absorption of glucose from the [[gastrointestinal tract]]. Increased peripheral use of glucose may be due to improved insulin binding to insulin receptors.<ref>{{cite journal | vauthors = Bailey CJ, Turner RC | title = Metformin | journal = The New England Journal of Medicine | volume = 334 | issue = 9 | pages = 574\u20139 | date = February 1996 | pmid = 8569826 | doi = 10.1056/NEJM199602293340906 }}</ref> The increase in insulin binding after metformin treatment has also been demonstrated in patients with [[Diabetes mellitus type 2|NIDDM]].<ref>{{cite journal | vauthors = Fantus IG, Brosseau R | title = Mechanism of action of metformin: insulin receptor and postreceptor effects in vitro and in vivo | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 63 | issue = 4 | pages = 898\u2013905 | date = October 1986 | pmid = 3745404 | doi = 10.1210/jcem-63-4-898 }}</ref>\n\nAMPK probably also plays a role in increased peripheral insulin sensitivity, as metformin administration increases AMPK activity in skeletal muscle.<ref>{{cite journal | vauthors = Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ | title = Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes | journal = Diabetes | volume = 51 | issue = 7 | pages = 2074\u201381 | date = July 2002 | pmid = 12086935 | doi = 10.2337/diabetes.51.7.2074 | doi-access = free }}</ref> AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in insulin-independent glucose uptake. Some metabolic actions of metformin do appear to occur by AMPK-independent mechanisms.\n\nMetformin has indirect [[antiandrogen]]ic effects in women with [[insulin resistance]], such as those with [[polycystic ovary syndrome]], due to its beneficial effects on insulin sensitivity.<ref name=\"NikolakisKyrgidis2019\">{{cite journal|vauthors=Nikolakis G, Kyrgidis A, Zouboulis CC |title=Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data|journal=American Journal of Clinical Dermatology|volume=20|issue=4|year=2019|pages=503\u201313|issn=1175-0561|doi=10.1007/s40257-019-00442-w|pmid=31073704 }}</ref> It may reduce [[testosterone]] levels in such women by 50%.<ref name=\"NikolakisKyrgidis2019\" />\n\n=== Pharmacokinetics ===\nMetformin has an oral [[bioavailability]] of 50\u201360% under [[fasting]] conditions, and is absorbed slowly.<ref name=PI>{{cite web |author=Bristol-Myers Squibb |author-link=Bristol-Myers Squibb |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf |title=Glucophage (metformin hydrochloride tablets) Label Information |date=27 August 2008 |access-date=2009-12-08 |publisher=U.S. Food and Drug Administration |url-status=live |archive-url=https://web.archive.org/web/20100922233241/http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf |archive-date=22 September 2010 |df= }}</ref><ref name=Heller>{{cite journal | vauthors = Heller JB |title=Metformin overdose in dogs and cats |journal=Veterinary Medicine |issue=April |year=2007 |pages=231\u201333 |url=http://www.aspca.org/site/DocServer/vetm0407_231-234.pdf?docID=11061 |url-status=dead |archive-url=https://web.archive.org/web/20071023063354/http://www.aspca.org/site/DocServer/vetm0407_231-234.pdf?docID=11061 |archive-date=2007-10-23 |df= }}</ref> Peak plasma concentrations (C<sub>max</sub>) are reached within one to three hours of taking immediate-release metformin and four to eight hours with extended-release formulations.<ref name=PI /><ref name = Heller /> The [[plasma protein binding]] of metformin is negligible, as reflected by its very high [[volume of distribution|apparent volume of distribution]] (300\u20131000&nbsp;l after a single dose). [[Steady state]] is usually reached in one or two days.<ref name=PI />\n\nMetformin has acid dissociation constant values (pK<sup>a</sup>) of 2.8 and 11.5, so exists very largely as the hydrophilic cationic species at physiological pH values. The metformin pK<sup>a</sup> values make it a stronger base than most other basic medications with less than 0.01% nonionized in blood. Furthermore, the [[Lipophilicity|lipid solubility]] of the nonionized species is slight as shown by its low logP value (log(10) of the distribution coefficient of the nonionized form between octanol and water) of \u22121.43. These chemical parameters indicate low lipophilicity and, consequently, rapid passive diffusion of metformin through cell membranes is unlikely. As a result of its low lipid solubility it requires the [[Membrane transport protein|transporter]] [[SLC22A1]] in order for it to enter cells.<ref>{{cite journal | vauthors = Rosilio C, Ben-Sahra I, Bost F, Peyron JF | title = Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia | journal = Cancer Letters | volume = 346 | issue = 2 | pages = 188\u201396 | date = May 2014 | pmid = 24462823 | doi = 10.1016/j.canlet.2014.01.006 }}</ref><ref name=Pry2015>{{cite journal | vauthors = Pryor R, Cabreiro F | title = Repurposing metformin: an old drug with new tricks in its binding pockets | journal = The Biochemical Journal | volume = 471 | issue = 3 | pages = 307\u201322 | date = November 2015 | pmid = 26475449 | pmc = 4613459 | doi = 10.1042/bj20150497 }}</ref> The logP of metformin is less than that of [[phenformin]] (\u22120.84) because two methyl substituents on metformin impart lesser lipophilicity than the larger phenylethyl side chain in [[phenformin]]. More lipophilic derivatives of metformin are presently under investigation with the aim of producing prodrugs with superior oral absorption than metformin.<ref>{{cite journal | vauthors = Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM | title = Clinical pharmacokinetics of metformin | journal = Clinical Pharmacokinetics | volume = 50 | issue = 2 | pages = 81\u201398 | date = February 2011 | pmid = 21241070 | doi = 10.2165/11534750-000000000-00000 }}</ref>\n\nMetformin is not [[drug metabolism|metabolized]]. It is [[clearance (medicine)|cleared]] from the body by [[renal physiology#Secretion|tubular secretion]] and excreted unchanged in the urine; metformin is undetectable in blood plasma within 24 hours of a single oral dose.<ref name=PI /><ref name=Robert /> The average [[biological half-life|elimination half-life]] in plasma is 6.2 hours.<ref name=PI /> Metformin is distributed to (and appears to accumulate in) [[red blood cell]]s, with a much longer elimination half-life: 17.6 hours<ref name=PI /> (reported as ranging from 18.5 to 31.5 hours in a single-dose study of nondiabetics).<ref name=Robert>{{cite journal | vauthors = Robert F, Fendri S, Hary L, Lacroix C, Andr\u00e9jak M, Lalau JD | title = Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects | journal = Diabetes & Metabolism | volume = 29 | issue = 3 | pages = 279\u201383 | date = June 2003 | pmid = 12909816 | doi = 10.1016/s1262-3636(07)70037-x }}</ref>\n\n== Chemistry ==\nMetformin hydrochloride (1,1-dimethylbiguanide hydrochloride) is freely-soluble in water, slightly soluble in ethanol, but almost insoluble in acetone, ether, or chloroform. The pK<sub>a</sub> of metformin is 12.4.<ref>{{cite book |doi = 10.1002/0471266949.bmc198|chapter = Diabetes Drugs: Present and Emerging|title = Burger's Medicinal Chemistry and Drug Discovery|year = 2010|last1 = Tilley|first1 = Jefferson|last2 = Grimsby|first2 = Joseph|last3 = Erickson|first3 = Shawn|last4 = Berthel|first4 = Steven|isbn = 978-0471266945}}</ref> The usual [[chemical synthesis|synthesis]] of metformin, originally described in 1922, involves the one-pot reaction of [[dimethylamine]] [[hydrochloride]] and [[2-cyanoguanidine]] over heat.<ref name = werner /><ref>{{cite journal | vauthors = Shapiro SL, Parrino VA, Freedman L |title=Hypoglycemic Agents. I Chemical Properties of \u03b2-Phenethylbiguanide. A New Hypoglycemic Agent |journal=[[J Am Chem Soc]] |volume=81 |issue=9 |year=1959 |pages=2220\u201325 |doi=10.1021/ja01518a052}}</ref>\n\n[[File:Metformin synthesis.svg|center|300px]]\n\nAccording to the procedure described in the 1975 Aron patent,<ref>{{cite journal |title=Proc\u00e9d\u00e9 de pr\u00e9paration de chlorhydrate de dim\u00e9thylbiguanide |journal=Patent FR 2322860|language=French|year=1975}}</ref> and the ''Pharmaceutical Manufacturing Encyclopedia'',<ref name=\"isbn0-8155-1526-X\">{{cite book |title=Pharmaceutical Manufacturing Encyclopedia (Sittig's Pharmaceutical Manufacturing Encyclopedia) |edition=3rd |volume=3 |publisher=William Andrew |location=Norwich, NY |year=2007 |page=2208 |isbn=978-0-8155-1526-5}}</ref> [[equivalent weight|equimolar]] amounts of dimethylamine and 2-cyanoguanidine are dissolved in [[toluene]] with cooling to make a [[Concentration#Qualitative description|concentrated]] solution, and an equimolar amount of [[hydrogen chloride]] is slowly added. The mixture begins to boil on its own, and after cooling, metformin hydrochloride [[precipitate]]s with a 96% [[Yield (chemistry)|yield]].\n\n== History ==\n[[File:Galega officinalis1UME.jpg|right|thumb|''Galega officinalis'', a natural source of galegine]]\n\nThe [[biguanide]] class of antidiabetic medications, which also includes the withdrawn agents [[phenformin]] and [[buformin]], originates from the [[Galega officinalis|French lilac]] or goat's rue (''Galega officinalis''), a plant used in folk medicine for several centuries.<ref name=Witters>{{cite journal | vauthors = Witters LA | title = The blooming of the French lilac | journal = The Journal of Clinical Investigation | volume = 108 | issue = 8 | pages = 1105\u20137 | date = October 2001 | pmid = 11602616 | pmc = 209536 | doi = 10.1172/JCI14178 }}</ref> ''Galega officinalis'' itself does not contain any of these medications, but isoamylene guanidine; phenformin, buformin, and metformin are chemically synthesized compounds composed of two guanidine molecules, and are more [[lipophilic]] than the plant-derived parent compound.<ref name=Witters/>\n\nMetformin was first described in the scientific literature in 1922, by Emil Werner and James Bell, as a product in the synthesis of ''N'',''N''-dimethylguanidine.<ref name = werner>{{cite journal | vauthors = Werner E, Bell J | title =The preparation of methylguanidine, and of \u03b2\u03b2-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides respectively |journal=J. Chem. Soc., Trans.|volume=121|pages=1790\u201395 |year=1922 |doi=10.1039/CT9222101790}}</ref> In 1929, Slotta and Tschesche discovered its sugar-lowering action in rabbits, finding it the most potent biguanide analog they studied.<ref name = slotta>See Chemical Abstracts, v.23, 42772 (1929) {{cite journal | vauthors = Slotta KH, Tschesche R|title= \u00dcber Biguanide, II.: Die blutzucker-senkende Wirkung der Biguanide|journal= Berichte der Deutschen Chemischen Gesellschaft (A and B Series)|volume=62|issue= 6|pages=1398\u20131405 |year=1929 |doi=10.1002/cber.19290620605}}</ref> This result was completely forgotten, as other [[guanidine]] analogs, such as the [[synthalin]]s, took over and were themselves soon overshadowed by insulin.<ref name= fifty>{{cite journal | veditors = Campbell IW |title=Metformin&nbsp;\u2013 life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007|journal=The British Journal of Diabetes & Vascular Disease|volume=7|issue=5|pages=247\u201352 |date=September 2007|doi=10.1177/14746514070070051001 }}</ref>\n\nInterest in metformin resumed at the end of the 1940s. In 1950, metformin, unlike some other similar compounds, was found not to decrease [[blood pressure]] and [[heart rate]] in animals.<ref name=\"pmid15405470\">{{cite journal | vauthors = Dawes GS, Mott JC | title = Circulatory and respiratory reflexes caused by aromatic guanidines | journal = British Journal of Pharmacology and Chemotherapy | volume = 5 | issue = 1 | pages = 65\u201376 | date = March 1950 | pmid = 15405470 | pmc = 1509951 | doi = 10.1111/j.1476-5381.1950.tb00578.x }}</ref> That year, Filipino physician Eusebio Y. Garcia<ref>About Eusebio Y. Garcia, see: {{cite web |url=http://sntpost.stii.dost.gov.ph/frames/aprtojun05/Search_for_DOST_NRCP_13to14.htm |title=Search for DOST-NRCP Dr. Eusebio Y. Garcia Award |vauthors=Carteciano J |date=2005 |publisher=Philippines Department of Science and Technology |access-date=2009-12-05 |url-status=dead |archive-url=https://web.archive.org/web/20091024075832/http://sntpost.stii.dost.gov.ph/frames/aprtojun05/Search_for_DOST_NRCP_13to14.htm |archive-date=24 October 2009 |df= }}</ref> used metformin (he named it Fluamine) to treat influenza; he noted the medication \"lowered the blood sugar to minimum physiological limit\" and was not toxic. Garcia believed metformin to have [[bacteriostatic]], [[Antiviral drug|antiviral]], [[antimalarial]], [[antipyretic]] and [[analgesic]] actions.<ref name=Garcia>Quoted from Chemical Abstracts, v.45, 24828 (1951) {{cite journal | vauthors = Garcia EY |title=Fluamine, a new synthetic analgesic and antiflu drug |journal=J Philippine Med Assoc |volume=26 |issue=7 |pages=287\u201393 |year=1950 |pmid=14779282}}</ref> In a series of articles in 1954, Polish pharmacologist Janusz Supniewski<ref name=\"pmid16766803\">About Janusz Supniewski, see: {{cite journal | vauthors = Wo\u0142kow PP, Korbut R | title = Pharmacology at the Jagiellonian University in Kracow, short review of contribution to global science and cardiovascular research through 400 years of history | journal = Journal of Physiology and Pharmacology | volume = 57 Suppl 1 | issue =  | pages = 119\u201336 | date = April 2006 | pmid = 16766803 | doi =  | url = http://www.jpp.krakow.pl/journal/archive/0406_s1/pdf/119_0406_s1_article.pdf | archive-url = https://web.archive.org/web/20091024211218/http://www.jpp.krakow.pl/journal/archive/0406_s1/pdf/119_0406_s1_article.pdf | df =  | url-status = dead | archive-date = 24 October 2009 | access-date = 22 December 2009 }}</ref> was unable to confirm most of these effects, including lowered blood sugar. Instead he observed antiviral effects in humans.<ref name=\"pmid13269290\">See Chemical Abstracts, v. 52, 22272 (1958) {{cite journal | vauthors = Supniewski J, Chrusciel T | title = [N-dimethyl-di-guanide and its biological properties] | language = Polish | journal = Archivum Immunologiae et Therapiae Experimentalis | volume = 2 | issue =  | pages = 1\u201315 | year = 1954 | pmid = 13269290 | doi =  }}</ref><ref name=supniewski2>Quoted from Chemical Abstracts, v.49, 74699 (1955) {{cite journal | vauthors = Supniewski J, Krupinska J |title=[Effect of biguanide derivatives on experimental cowpox in rabbits] |language=French |journal=Bulletin de l'Academie Polonaise des Sciences, Classe 3: Mathematique, Astronomie, Physique, Chimie, Geologie et Geographie |volume=2(Classe II) |issue= |pages=161\u201365 |year=1954}}</ref>\n\nFrench diabetologist Jean Sterne studied the antihyperglycemic properties of [[galegine]], an [[alkaloid]] isolated from ''[[Galega officinalis]]'', which is related in structure to metformin and had seen brief use as an antidiabetic before the synthalins were developed.<ref name=Bailey>{{cite journal | vauthors = Bailey CJ, Day C |title=Metformin: its botanical background |journal=Practical Diabetes International |volume=21 |issue=3 |pages=115\u201317 |year=2004 |doi=10.1002/pdi.606 |url=http://www3.interscience.wiley.com/cgi-bin/fulltext/108564133/HTMLSTART|archive-url=https://archive.today/20121217224908/http://www3.interscience.wiley.com/cgi-bin/fulltext/108564133/HTMLSTART|url-status=dead|archive-date=2012-12-17}}</ref> Later, working at Laboratoires Aron in Paris, he was prompted by Garcia's report to reinvestigate the blood sugar-lowering activity of metformin and several biguanide analogs. Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name \"Glucophage\" (glucose eater) for the medication and published his results in 1957.<ref name= fifty /><ref name=Bailey />\n\nMetformin became available in the [[British National Formulary]] in 1958. It was sold in the UK by a small Aron subsidiary called Rona.<!--Being a generic drug, it was at a commercial disadvantage; phenformin and buformin were marketed as being more potent and were supported by large pharmaceutical companies with a large sales force. As a result, metformin was used mostly in Scotland and Northern Ireland, while phenformin and buformin achieved worldwide clinical acceptance.--><ref name=\"pmid16402501\">{{cite journal | vauthors = Hadden DR | title = Goat's rue\u2014French lilac\u2014Italian fitch\u2014Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection | journal = The Journal of the Royal College of Physicians of Edinburgh | volume = 35 | issue = 3 | pages = 258\u201360 | date = October 2005 | pmid = 16402501 | doi =  | url = http://www.rcpe.ac.uk/journal/issue/journal_35_3/hadden_goats%20rue.pdf }}</ref>\n\nBroad interest in metformin was not rekindled until the withdrawal of the other biguanides in the 1970s. Metformin was approved in Canada in 1972,<ref>{{cite journal | vauthors = Lucis OJ | title = The status of metformin in Canada | journal = Canadian Medical Association Journal | volume = 128 | issue = 1 | pages = 24\u20136 | date = January 1983 | pmid = 6847752 | pmc = 1874707 }}</ref> but did not receive approval by the U.S. [[Food and Drug Administration]] (FDA) for type 2 diabetes until 1994.<ref name = FDAapproval>{{cite press release |title=FDA Approves New Diabetes Drug |date=30 December 1994 |publisher=U.S. [[Food and Drug Administration]] (FDA) |access-date=2007-01-06 |url=https://www.fda.gov/bbs/topics/ANSWERS/ANS00627.html |archive-url=https://web.archive.org/web/20070929152824/https://www.fda.gov/bbs/topics/ANSWERS/ANS00627.html |archive-date=29 September 2007 |url-status=dead }}</ref> Produced under license by [[Bristol-Myers Squibb]], Glucophage was the first branded formulation of metformin to be marketed in the U.S., beginning on 3 March 1995.<ref>{{cite web | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf | title=Drug Approval Package: Glucophage (metformin) | website=U.S. [[Food and Drug Administration]] (FDA) | archive-url=https://web.archive.org/web/20200205051949/https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf | archive-date=2020-02-05 | url-status=live | access-date=8 January 2007}}</ref> [[generic drug|Generic]] formulations are now available in several countries, and metformin is believed to have become the world's most widely prescribed antidiabetic medication.<ref name=Bailey />\n\n==Society and culture==\n\n=== Environmental ===\nMetformin and its major transformation product guanylurea are present in wastewater treatment plant effluents and regularly detected in surface waters. Guanylurea concentrations above 200 \u03bcg L<sup>\u22121</sup> have been measured in a German river which are amongst the highest reported for pharmaceutical transformation products in aquatic environments.<ref name=\"pmid30350841\">{{cite journal | vauthors = Posselt M, Jaeger A, Schaper JL, Radke M, Benskin JP | title = Determination of polar organic micropollutants in surface and pore water by high-resolution sampling-direct injection-ultra high performance liquid chromatography-tandem mass spectrometry | journal = Environ. Sci.: Process. Impacts | volume = 20 | issue = 12 | pages = 1716\u20131727 | date = December 2018 | pmid = 30350841 | doi = 10.1039/C8EM00390D | doi-access = free }}</ref>\n\n=== Formulations ===\n{{anchor|Formulations}}\n[[File:Metformin 500mg Tablets.jpg|thumb|right|Generic metformin 500-mg tablets, as sold in the United Kingdom]]\n<!-- editors, please note that the trade names noted above redirect to this section i.e. Metformin#Formulations-->\nThe name \"Metformin\" is the [[British Approved Name|BAN]], [[United States Adopted Name|USAN]] and [[International Nonproprietary Name|INN]] for the medication. It is sold under several [[trade name]]s, including Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor, Metfogamma and Glifor.\n\nLiquid metformin is sold under the name Riomet in India. Each 5&nbsp;ml of Riomet is equivalent to the 500-mg tablet form.<ref>{{cite web|url=http://www.rxwiki.com/Metformin|title=Metformin|date=9 July 2012|work=rxwiki|url-status=live|archive-url=https://web.archive.org/web/20130915084453/http://www.rxwiki.com/metformin|archive-date=15 September 2013|df=}}</ref>\n\nMetformin IR (immediate release) is available in 500, 850, and 1000-mg tablets.  All of these are available as generic medications in the U.S.\n\nMetformin SR (slow release) or XR (extended release) was introduced in 2004. It is available in 500, 750, and 1000-mg strengths, mainly to counteract common gastrointestinal side effects, as well as to increase compliance by reducing [[pill burden]]. No difference in effectiveness exists between the two preparations.\n\n==== Combination with other medications ====\nWhen used for type 2 diabetes, metformin is often prescribed in combination with other medications.\n\nSeveral are available as [[fixed-dose combination]]s, to reduce pill burden and simplify administration.<ref name=FDC>{{cite journal | vauthors = Bailey CJ, Day C | title = Fixed-dose single tablet antidiabetic combinations | journal = Diabetes, Obesity & Metabolism | volume = 11 | issue = 6 | pages = 527\u201333 | date = June 2009 | pmid = 19175373 | doi = 10.1111/j.1463-1326.2008.00993.x }}</ref>\n\n==== Thiazolidinediones (glitazones) ====\n\n====Rosiglitazone==== <!-- target of redirect from Avandamet -->\n{{anchor|Rosiglitazone}}\nA combination of metformin and [[rosiglitazone]] was released in 2002 and sold as Avandamet by [[GlaxoSmithKline]].<ref>{{cite press release |title=FDA Approves GlaxoSmithKline's Avandamet (rosiglitazone maleate and metformin HCl), The Latest Advancement in the Treatment of Type 2 Diabetes |publisher=[[GlaxoSmithKline]] |date=12 October 2002 |access-date=2006-12-27 |url=http://www.docguide.com/news/content.nsf/news/8525697700573E1885256C4F0075B2B3 |url-status=live |archive-url=https://web.archive.org/web/20070121050431/http://www.docguide.com/news/content.nsf/news/8525697700573E1885256C4F0075B2B3 |archive-date=21 January 2007 |df= }}</ref>\n\nBy 2009 it had become the most popular metformin combination.<ref>{{cite web |url= http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252010/674969/article.pdf |title= 2009 Top 200 branded drugs by total prescriptions |url-status=dead |archive-url= https://web.archive.org/web/20110714111215/http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252010/674969/article.pdf |archive-date= 2011-07-14 |df=  }}&nbsp;{{small|(96.5&nbsp;KB)}}. ''Drug Topics'' (17 June 2010). Retrieved 2 September 2010.</ref>\n\nIn 2005, the stock of Avandamet was removed from the market, after inspections showed the factory where it was produced was violating [[good manufacturing practice]]s.<ref>{{cite press release |title=Questions and Answers about the Seizure of Paxil CR and Avandamet |publisher=U.S. [[Food and Drug Administration]] |date=4 March 2005 |access-date=2006-12-27 |url=https://www.fda.gov/oc/qanda/PaxilandAvandamet.html |archive-url=https://web.archive.org/web/20071014014507/https://www.fda.gov/oc/qanda/PaxilandAvandamet.html |archive-date=14 October 2007 |url-status=dead }}</ref> The medication pair continued to be prescribed separately and Avandamet was again available by the end of that year. A generic formulation of metformin/rosiglitazone from [[Teva Pharmaceutical Industries|Teva]] received tentative approval from the FDA and reached the market in early 2012.<ref>{{cite press release |url=https://www.reuters.com/article/inPlayBriefing/idUSIN20070927170530TEVA20070927 |title=Teva Pharm announces settlement of generic Avandia, Avandamet, and Avandaryl litigation with GlaxoSmithKline |publisher=Reuters |date=27 September 2007 |access-date=2009-02-17}}</ref>\n\nHowever, following a [[meta-analysis]] in 2007 that linked the medication's use to an increased risk of [[Myocardial infarction|heart attack]],<ref name=\"pmid17517853\">{{cite journal | vauthors = Nissen SE, Wolski K | title = Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes | journal = The New England Journal of Medicine | volume = 356 | issue = 24 | pages = 2457\u201371 | date = June 2007 | pmid = 17517853 | doi = 10.1056/NEJMoa072761 }}</ref>  concerns were raised over the safety of medicines containing rosiglitazone. In September 2010 the [[European Medicines Agency]] (EMA) recommended that the medication be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks.<ref name=\"ema_recommend_suspend\">{{cite web | url = http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=false | publisher = European Medicines Agency | work = News and Events | title = European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim | format =  | access-date =  | url-status=live | archive-url = https://web.archive.org/web/20150924052044/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2010%2F09%2Fnews_detail_001119.jsp&murl=menus%2Fnews_and_events%2Fnews_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=false | archive-date = 2015-09-24 | df =  | date = 2018-09-17 }}</ref><ref name=\"bbc_ema_suspension\">{{cite news | url = https://www.bbc.co.uk/news/health-11397645 | publisher = BBC News | title = Call to 'suspend' diabetes drug | format =  | work =  | access-date =  | date = 2010-09-23 | url-status=live | archive-url = https://web.archive.org/web/20100924044603/http://www.bbc.co.uk/news/health-11397645 | archive-date = 2010-09-24 | df =  }}</ref>\n\nIt was withdrawn from the market in the UK and India in 2010,<ref name=ban>{{cite web|url=http://cdsco.nic.in/html/drugsbanned.html |title=Drugs banned in India |publisher=Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India |access-date=2013-09-17 |url-status=dead |archive-url=https://web.archive.org/web/20150221053621/http://cdsco.nic.in/html/drugsbanned.html |archive-date=2015-02-21 |df= }}</ref> and in New Zealand and South Africa in 2011.<ref name=\"Stuff.co.nz_4669573\">{{cite news |url=http://www.stuff.co.nz/4669573 |title=Diabetes drug withdrawn |date=17 February 2011 |agency=[[NZPA]] |work=[[Stuff.co.nz]] |access-date=5 November 2011}}</ref> From November 2011 until November 2013 the FDA<ref>{{cite news | url = https://www.nytimes.com/2010/02/20/health/policy/20avandia.html | title = Controversial Diabetes Drug Harms Heart, U.S. Concludes | first = Gardiner | last = Harris | name-list-format = vanc | work = [[The New York Times]] | date = 19 February 2010 | url-status=live | archive-url = https://web.archive.org/web/20170319173917/http://www.nytimes.com/2010/02/20/health/policy/20avandia.html | archive-date = 19 March 2017 | df =  }}</ref> did not allow rosiglitazone or metformin/rosiglitazone to be sold without a prescription; moreover, makers were required to notify patients of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies.<ref>{{cite news| url=http://yourlife.usatoday.com/health/medical/heartdisease/story/2011/05/Diabetes-drug-Avandia-to-be-pulled-from-retail-shelves/47316450/1?csp=34news | work=USA Today | title=Most Popular E-mail Newsletter | date=2011-05-24}}</ref>\n\nIn November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label [[randomized control trial]]), which failed to show elevated risk of heart attack or death associated with the medication.<ref name=\"urlGlaxo's Avandia Cleared From Sales Restrictions by FDA \u2013 Bloomberg\">{{cite news | url = https://www.bloomberg.com/news/2013-11-25/glaxo-s-avandia-cleared-from-sales-restrictions-by-fda.html | title = Glaxo's Avandia Cleared From Sales Restrictions by FDA | publisher = Bloomberg | work =  | access-date =  | url-status=live | archive-url = https://web.archive.org/web/20141109083451/http://www.bloomberg.com/news/2013-11-25/glaxo-s-avandia-cleared-from-sales-restrictions-by-fda.html | archive-date = 2014-11-09 | df =  }}</ref><ref>{{cite press release | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm | title = FDA requires removal of certain restrictions on the diabetes drug Avandia | date = 25 November 2013 | website = U.S. [[Food and Drug Administration]] (FDA) | url-status=dead | archive-url = https://web.archive.org/web/20150504051733/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm | archive-date = 4 May 2015 | df =  }}</ref><ref>{{cite web|url=http://blogs.nature.com/news/2013/11/fda-reverses-stance-on-controversial-diabetes-drug.html|title=US agency reverses stance on controversial diabetes drug|publisher=|url-status=live|archive-url=https://web.archive.org/web/20151211005224/http://blogs.nature.com/news/2013/11/fda-reverses-stance-on-controversial-diabetes-drug.html|archive-date=2015-12-11|df=}}</ref>\n\n===== Pioglitazone =====\n{{anchor|Pioglitazone}}\nThe combination of [[Pioglitazone/metformin|metformin and pioglitazone]] (Actoplus Met, Piomet, Politor, Glubrava) is available in the US and in the European Union.<ref>{{cite web | title=Glubrava EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/glubrava | access-date=31 March 2020}}</ref><ref>{{cite web | title=Competact EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/competact | access-date=31 March 2020}}</ref><ref>{{cite web | title=Pioglitazone (marketed as Actos, Actoplus Met, Duetact, and Oseni) Information | website=U.S. [[Food and Drug Administration]] (FDA) | date=11 January 2017 | url=http://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/pioglitazone-marketed-actos-actoplus-met-duetact-and-oseni-information | access-date=31 March 2020}}</ref><ref>{{cite web | title=FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function | website=U.S. [[Food and Drug Administration]] (FDA) | date=3 April 2013 | url=http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain | access-date=31 March 2020}}</ref><ref>{{cite web | title=FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer | website=U.S. [[Food and Drug Administration]] (FDA) | date=4 August 2011 | url=http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone | access-date=31 March 2020}}</ref>\n\n===== DPP-4 inhibitors =====\n{{anchor|DPP-4 inhibitors}}\n[[Dipeptidyl peptidase-4 inhibitor]]s inhibit [[dipeptidyl peptidase-4]] and thus reduce [[glucagon]] and blood glucose levels.\n\nDPP-4 inhibitors combined with metformin include a [[sitagliptin/metformin]] combination and a [[saxagliptin]] combination (Komboglyze), and with [[alogliptin]] as Kazano among others.\n\nMetformin combined with [[linagliptin]] is marketed under the trade name Jentadueto.<ref>{{cite web | title=Jentadueto EPAR | website=European Medicines Agency | url=https://www.ema.europa.eu/en/medicines/human/EPAR/jentadueto | access-date=31 March 2020}}</ref><ref>{{cite web | title=Jentadueto- linagliptin and metformin hydrochloride tablet, film coated | website=DailyMed | date=18 July 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd9b86-0d18-95d4-2bc7-05591bfdd597 | access-date=31 March 2020}}</ref>\n\n===== Sulfonylureas =====\n[[Sulfonylurea]]s act by increasing insulin release from the [[beta cell]]s in the [[pancreas]]. Metformin is available combined with the sulfonylureas [[glipizide]] (Metaglip) and [[glibenclamide]] (US: glyburide) (Glucovance).\n\nGeneric formulations of metformin/glipizide and metformin/glibenclamide are available (the latter is more popular).<ref name=Top200Generics>{{cite web |url= http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf |title= The Use of Medicines in the United States: Review of 2010 |url-status=live |archive-url= https://web.archive.org/web/20110422165905/http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf |archive-date= 2011-04-22 |df=  }}&nbsp;{{small|(1.79&nbsp;MB)}}. IMS Institute for Healthcare Informatics (April 2011). Retrieved 28 April 2011.</ref>\n\n===== Meglitinide =====\n[[Meglitinide]]s are similar to [[sulfonylurea]]s.\n\nA [[repaglinide]]/metformin combination is sold as Prandimet.\n\n===== Triple combination =====\nThe combination of metformin with pioglitazone and glibenclamide<ref>{{cite journal | vauthors = Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C | title = Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy | journal = The Journal of the Association of Physicians of India | volume = 51 | pages = 1061\u20134 | date = November 2003 | pmid = 15260389 }}</ref> is available in India as Triformin.\n\n=== Impurities ===\n{{Anchor|impurities}}\n{{See also|Ranitidine#impurities}}\n\nIn December 2019, the U.S. [[Food and Drug Administration]] (FDA) announced that it learned that some metformin medicines manufactured outside the United States might contain a nitrosamine impurity called [[N-nitrosodimethylamine]] (NDMA), classified as a probable human carcinogen, at low levels.<ref name=\"FDA2019NDMA\">{{cite web | title=Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S. | website=U.S. [[Food and Drug Administration]] (FDA) | date=5 December 2019 | url=http://www.fda.gov/news-events/press-announcements/statement-janet-woodcock-md-director-fdas-center-drug-evaluation-and-research-impurities-found | access-date=4 February 2020}} {{PD-notice}}</ref> Health Canada announced that it was assessing NDMA levels in metformin.<ref name=\"HealthCanada\">{{cite web | title=Recalls and safety alerts | website=Health Canada evaluating NDMA in metformin drugs | date=5 December 2019 | url=https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71831a-eng.php | access-date=4 February 2020}}</ref>\n\nIn February 2020, the FDA found that NDMA levels in tested metformin samples did not exceed the acceptable daily intake.<ref>{{cite web | title=Laboratory Tests - Metformin | website=U.S. [[Food and Drug Administration]] (FDA) | date=3 February 2020 | url=http://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-metformin | access-date=4 February 2020}}</ref><ref>{{cite web | title=FDA Updates and Press Announcements on NDMA in Metformin | website=U.S. Food and Drug Administration | date=4 February 2020 | url=http://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin | access-date=4 February 2020}}</ref>\n\n== Research ==\nMetformin has been studied for its effects on multiple other conditions, including:\n* [[Non-alcoholic fatty liver disease]].<ref name=\"Marchesini\">{{cite journal | vauthors = Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N | title = Metformin in non-alcoholic steatohepatitis | journal = Lancet | volume = 358 | issue = 9285 | pages = 893\u20134 | date = September 2001 | pmid = 11567710 | doi = 10.1016/S0140-6736(01)06042-1 }}</ref><ref>{{cite journal | vauthors = Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H | title = Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review | journal = Journal of Pediatric Gastroenterology and Nutrition | volume = 48 | issue = 5 | pages = 587\u201396 | date = May 2009 | pmid = 19412008 | doi = 10.1097/MPG.0b013e31818e04d1 }}</ref><ref name=\":2\" />\n* [[Premature puberty]].<ref name=\":2\">{{cite journal | vauthors = Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F | title = Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis | journal = Cochrane Database of Systematic Reviews | volume = 24 | issue = 1 | pages = CD005166 | date = January 2007 | pmid = 17253544 | doi = 10.1002/14651858.CD005166.pub2 }} {{Retracted |doi=10.1002/14651858.cd005166.pub3}}</ref><ref>{{cite journal | vauthors = Ib\u00e1\u00f1ez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F | title = Metformin treatment to prevent early puberty in girls with precocious pubarche | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 91 | issue = 8 | pages = 2888\u201391 | date = August 2006 | pmid = 16684823 | doi = 10.1210/jc.2006-0336 | doi-access = free }}</ref>\n* [[anti-cancer|Cancer]].<ref name=\"pmid20442309\">{{cite journal | vauthors = Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F | title = Metformin in cancer therapy: a new perspective for an old antidiabetic drug? | journal = Molecular Cancer Therapeutics | volume = 9 | issue = 5 | pages = 1092\u20139 | date = May 2010 | pmid = 20442309 | doi = 10.1158/1535-7163.MCT-09-1186 | doi-access = free }}</ref><ref name=\"ReferenceA\">{{cite journal | vauthors = Malek M, Aghili R, Emami Z, Khamseh ME | title = Risk of cancer in diabetes: the effect of metformin | journal = ISRN Endocrinology | volume = 2013 | pages = 636927 | date = September 2013 | pmid = 24224094 | pmc = 3800579 | doi = 10.1155/2013/636927 }}</ref>\n* [[Cardiovascular disease]] in people with diabetes.<ref name=\"Cam2017\">{{cite journal | vauthors = Campbell JM, Bellman SM, Stephenson MD, Lisy K | title = Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis | journal = Ageing Research Reviews | volume = 40 | pages = 31\u201344 | date = November 2017 | pmid = 28802803 | doi = 10.1016/j.arr.2017.08.003 }}</ref>\n* While metformin may reduce body weight in persons with fragile X syndrome, it is uncertain whether it improves neurological or psychiatric symptoms.<ref>{{cite journal |vauthors=Gantois I, Popic J, Khoutorsky A, Sonenberg N |display-authors=3 |title=Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders |journal=Annu. Rev. Med. |volume=70 |issue= |pages=167\u2013181 |date=January 2019 |pmid=30365357 |doi=10.1146/annurev-med-081117-041238 |url=}}</ref>\n* Aging (''[[Caenorhabditis elegans|C. elegans]]'' and [[Acheta domesticus|crickets]]).<ref name=\"Pry2015\" /> A 2017 review found that people with diabetes who were taking metformin had lower all-cause mortality. They also had reduced cancer and cardiovascular disease compared with those on other therapies.<ref name=\"Cam2017\" /> {{As of|2016}}, it is being studied to see what effect it may have on aging.<ref>{{cite journal |vauthors=Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA |display-authors=3 |title=Metformin as a Tool to Target Aging |journal=Cell Metabolism |date=June 2016 |volume=23 |issue=6 |pages=1060\u20135 |doi=10.1016/j.cmet.2016.05.011|pmid=27304507 |pmc=5943638 }}</ref>\n\n== References ==\n{{Reflist}}\n\n== Further reading ==\n* {{cite journal |vauthors=Markowicz-Piasecka M, Huttunen KM, Mateusiak L, Mikiciuk-Olasik E, Sikora J |display-authors=3 |title=Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics |journal=Curr. Pharm. Des. |volume=23 |issue=17 |pages=2532\u20132550 |date=2017 |pmid=27908266 |doi=10.2174/1381612822666161201152941 |url=}}\n* {{cite journal |vauthors=McCreight LJ, Bailey CJ, Pearson ER |title=Metformin and the gastrointestinal tract |journal=Diabetologia |volume=59 |issue=3 |pages=426\u201335 |date=March 2016 |pmid=26780750 |pmc=4742508 |doi=10.1007/s00125-015-3844-9 |url=}}\n* {{cite journal |vauthors=Moin T, Schmittdiel JA, Flory JH, Yeh J, Karter AJ, Kruge LE, Schillinger D, Mangione CM, Herman WH, Walker EA |display-authors=3 |title=Review of Metformin Use for Type 2 Diabetes Prevention |journal=Am J Prev Med |volume=55 |issue=4 |pages=565\u2013574 |date=October 2018 |pmid=30126667 |pmc=6613947 |doi=10.1016/j.amepre.2018.04.038 |url=}}\n* {{cite journal |vauthors=Rena G, Hardie DG, Pearson ER |title=The mechanisms of action of metformin |journal=Diabetologia |volume=60 |issue=9 |pages=1577\u20131585 |date=September 2017 |pmid=28776086 |pmc=5552828 |doi=10.1007/s00125-017-4342-z |url=}}\n* {{cite journal |vauthors=Sanchez-Rangel E, Inzucchi SE |title=Metformin: clinical use in type 2 diabetes |journal=Diabetologia |volume=60 |issue=9 |pages=1586\u20131593 |date=September 2017 |pmid=28770321 |doi=10.1007/s00125-017-4336-x |url=|doi-access=free }}\n* {{cite journal |vauthors=Zhou J, Massey S, Story D, Li L |display-authors=3 |title=Metformin: An Old Drug with New Applications |journal=Int J Mol Sci |volume=19 |issue=10 |pages= 2863|date=September 2018 |pmid=30241400 |pmc=6213209 |doi=10.3390/ijms19102863 |url=}}\n* {{cite journal |vauthors=Zhou T, Xu X, Du M, Zhao T, Wang J |display-authors=3 |title=A preclinical overview of metformin for the treatment of type 2 diabetes |journal=Biomed. Pharmacother. |volume=106 |issue= |pages=1227\u20131235 |date=October 2018 |pmid=30119191 |doi=10.1016/j.biopha.2018.07.085 |url=}}\n\n== External links ==\n{{Commons category|Metformin}}\n* {{cite web| url = https://druginfo.nlm.nih.gov/drugportal/name/metformin | publisher = U.S. National Library of Medicine| work = Drug Information Portal| title = Metformin }}\n\n{{Merck Serono|state=autocollapse}}\n{{Oral hypoglycemics and insulin analogs|state=collapsed}}\n{{Portal bar|Pharmacy and pharmacology|Medicine}}\n\n[[Category:Biguanides]]\n[[Category:Drugs with unknown mechanisms of action]]\n[[Category:Guanidines]]\n[[Category:Merck brands]]\n[[Category:World Health Organization essential medicines]]\n[[Category:RTT]]\n", "name_user": "Sbelknap", "label": "safe", "comment": "", "url_page": "//en.wikipedia.org/wiki/Metformin"}
